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1 Summary 
The AP-1 transcription factor is a central player in a multitude of biological processes from 
normal development to neoplastic transformation causing cancer. Junb, a subunit of AP-1, is 
special by the fact that it has at the same time activator and repressor functions. While 
positively regulated Junb target genes are principally required for proper vascular 
development, negative regulation of cytokines is of crucial importance to suppress pro-
inflammatory and tumorigenic phenotypes. In this work, I approached this double-edge role 
of Junb by addressing two scientific questions: the mode of operation of Junb as negative 
transcription regulator and its impact in the ER stress response and apoptosis. First, I could 
show that, in addition to the general view of being an inhibitor of AP-1 by absorbing Jun 
activity, Junb also represses genes by epigenetic mechanisms. Although Junb did regulate 
neither the levels of histone acetylation nor the expression of HDACs, DNMTs and co-
repressor complexes, few genes showed differential induction by HDAC inhibitors in wild-
type and Junb-deficient fibroblasts. Presumably, these genes may be regulated through a yet 
to be identified Junb-dependent mechanism involving HDACs. Moreover, Junb regulated the 
DNA methylation of the imprinting control region of the gene H19. The molecular 
mechanisms involved in Junb-dependent epigenetic regulation appear to be novel and very 
unusual for an AP-1 member and remains to be fully solved. Secondly, I investigated the role 
of Junb in ER stress, a condition that has been described to contribute to hypoxia tolerance 
and tumor progression. Although Junb deficiency resulted in minor changes in the ER stress-
triggered unfolded protein response (UPR), Junb-ablated MEFs were resistant towards 
apoptosis. Very high levels of activated pro-survival kinases resulted in aberrant post-
translational modification of BH3-only proteins Bim and Bad and subsequent failure in 
mitochondria permeabilization and caspases activation. A soluble factor, most likely Pdgfb, 
elicited a pro-survival autocrine loop causative for the apoptosis resistance in absence of 
Junb. In summary, the negative regulation of cytokines and growth factors by Junb accounts 
for most of the deleterious effects observed in absence of Junb, except for the angiogenesis 
phenotype. Thus, the understanding of how Junb represses genes and the targeting of this 
specific mechanism would represent a promising therapeutic approach to treat in the future 
inflammatory disease and cancer. 
. 
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2 Zusammenfassung 
Der Transkriptionsfaktor AP-1 ist ein zentraler Akteur in einer großen Zahl biologischer 
Prozesse von der normalen Entwicklung bis zur neoplastischen Transformation, die zu Krebs 
führt. Junb, eine Untereinheit von AP-1, ist  dadurch außergewöhnlich, dass Junb gleichzeitig 
Aktivator- und Repressorfunktionen hat. Während positiv regulierte Junb Zielgene in der 
Hauptsache für eine geordnete vaskuläre Entwicklung erforderlich sind, ist die negative 
Regulation von Zytokinen für die Unterdrückung von entzündlichen und tumorgenen 
Phänotypen von entscheidender Bedeutung. In der vorliegenden Arbeit habe ich diese 
zweischneidige Rolle von Junb analysiert, indem ich zwei wissenschaftliche Fragen 
bearbeitete: die Arbeitsweise von Junb als negativer transkriptioneller Regulator und seinen 
Einfluss in der ER Stressantwort und Apoptose. Als Erstes konnte ich zeigen, dass zusätzlich 
zur generellen Ansicht, dass JunB AP-1 durch Abfangen der Jun Aktivität hemmt, Junb Gene 
auch über epigenetische Mechanismen inaktiviert. Obwohl Junb weder die Menge an 
Histonazetylierung, noch die Expression von HDACs, DNMTs und Ko-Repressorkomplexen 
regulierte, zeigten einige Gene in Wildtyp und Junb-defizienten Fibroblasten unterschiedliche 
Induktion nach HDAC Inhibitorgabe. Dies lässt vermuten, dass diese Gene durch einen noch 
zu identifizierenden Junb-abhängigen Mechanismus via HDACs reguliert sein könnten. 
Darüber hinaus regulierte Junb die DNA Methylierung der Imprinting Kontrollregion des 
H19 Gens. Der molekulare Mechanismus dieser Junb-abhängigen epigenetischen Regulation 
scheint neuartig und sehr ungewöhnlich für ein AP-1 Mitglied und muss noch vollständig 
geklärt werden. Als Zweites habe ich die Aufgabe von Junb im ER Stress untersucht, einem 
Zustand der mit Hypoxietoleranz und Tumorprogression im Zusammenhang steht. Obwohl 
das Fehlen von Junb zu minimalen Veränderungen im ER Stress induzierten 
Stoffwechselweg UPR führt, waren MEFs ohne Junb Apoptose-resistent. Sehr hohe Level an 
aktivierten überlebensstimulierenden Kinasen resultierten in veränderter posttranslationaler 
Modifikation der „BH-3 only“ Proteine Bim und Bad und im nachfolgendem Ausbleiben der 
Mitochondrienpermeabilisierung und Caspase-Aktivierung. Ein löslicher Faktor, sehr 
wahrscheinlich Pdgfb, löste einen überlebensfördernden autokrinen geschlossenen Regelkreis 
aus, der für die Apoptoseresistenz in Abwesenheit von Junb ursächlich ist. Zusammengefasst 
ist die negative Regulation von Zyktokinen und Wachstumsfaktoren durch Junb für die 
meisten schädlichen Auswirkungen verantwortlich, die mit Ausnahme des 
Angiogenesephänotyps, in Abwesenheit von Junb auftreten. Daher würde das Verständnis 
darüber wie Junb Gene reprimiert und der somit mögliche gezielte Eingriff in diesen 
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Mechanismus ein viel versprechender therapeutischer Ansatz bieten, um künftig entzündliche 
Erkrankungen und Krebs zu behandeln. 
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3 Introduction 
The development of multicellular organisms is very complex and, thus, requires a tight 
regulation. Developmental programs include cell division, growth, migration and 
differentiation, which are all governed by complex signaling pathways resulting in changes in 
gene expression. Proper gene expression is absolutely essential for the maintenance of the 
cellular integrity of higher organisms, while aberrant gene expression results in the 
development of various diseases such as cancer. Gene expression is regulated on multiple 
levels, from transcription by transcription factors to translation and post-translational 
modifications.  
Much of our current knowledge about the characteristics of transcription factors comes from 
the discovery and study of Activating Protein-1 (AP-1). Since the AP-1 transcription factor 
mediates gene regulation in response to a wide variety of physiological and pathological 
stimuli, it is a central player in a multitude of cellular processes from normal development to 
neoplastic transformation causing cancer. Despite the fact that AP-1 has been identified more 
than two decades ago, it still maintains a lot of its mystery. Deciphering the complexity of the 
AP-1 genetic network should help to better understand how the cell performs the critically 
fine tuning of its fate. 
3.1 The transcription factor AP-1 
The activating protein-1 (AP-1) is a transcription factor principally composed of dimers 
between the Jun (Jun, Junb and Jund), Fos (Fos, Fosb, Fra-1, Fra-2), ATF (activating 
transcription factor, Atf2, LRF-1/ATF-3, Batf, Jdp1, Jdp2) and Maf (c-Maf, MafB, MafA, 
MafG/F/K) protein families. AP-1 is at the receiving end of signaling cacades elicited by a 
plethora of physiological and pathological stimuli, including cytokines, growth factors and 
stress signals, bacterial and viral infections as well as oncogenic stimuli and it regulates, upon 
activation, numerous target genes (Hess et al., 2004). 
3.1.1 Biochemical properties of AP-1 
A common feature of AP-1 family members is the conserved bZIP domain. The 
evolutionarily conserved bZIP domain consists of a leucine zipper region, which allows 
dimerization of the proteins, combined with a basic DNA binding domain that requires 
dimerization to bind DNA. While the Fos proteins (Fos, Fosb, Fra-1, Fra-2) can only 
heterodimerize with members of the Jun family, the Jun proteins (Jun, Junb, Jund) can both 
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homo- and heterodimerize with Fos or ATF members to form transcriptionally active 
complexes. In addition to the well-characterized bZIP domain, the AP-1 family members 
comprise a transactivation domain, which differs between the individual Jun and Fos proteins 
with regard to its potential (Angel and Karin, 1991; Hess et al., 2004). Whereas Jun, Fos and 
Fosb are considered strong transactivators, Junb, Jund, Fra-1 and Fra-2 exhibit only weak 
transactivation potential. Under specific circumstances, the latter may even act as repressors 
of AP-1 activity by competing for binding to AP-1 sites or by forming inactive heterodimers 
with Jun, Fos or FosB (Angel and Karin, 1991; Chiu et al., 1989; Hess et al., 2004). 
AP-1 regulates gene expression through binding to the palindromic TPA Responsive Element 
(TRE) consensus sequences. The TRE, composed of the 5’-TGA G/C TCA-3’ DNA 
sequence, was originally identified in the human collagenase and metallothionein IIa genes 
and was called so because it is strongly induced by the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA). Although the main DNA element bound by AP-1 is 
the TRE, some dimers have also been described to bind to the related cAMP-Response 
Element or CRE. The CRE differs from the TRE by a single base insertion and has the DNA 
consensus sequence 5’-TGA GC TCA-3’ (Angel and Karin, 1991). 
3.1.2 Transcriptional and post-transcriptional regulation of AP-1 
The net AP-1 activity in a given cell is regulated by a broad range of physiological and 
pathological stimuli. It is achieved at two major levels: extracellular stimuli can modulate 
both the abundance and the activity of AP-1 proteins.  
The abundance of AP-1 proteins is regulated by transcription of genes encoding AP-1 
subunits, control of the stability of their mRNAs and turnover of pre-existing or newly 
synthesized AP-1 subunits (Karin et al., 1997).  
Post-translational modifications and interactions with other transcription factors or cofactors 
modulate AP-1 activity (Hess et al., 2004). Post-translational modification has been 
extensively studied for the AP-1 member Jun, that becomes phosphorylated and activated by 
the Stress Activated Protein Kinase (SAPK) cascade (Minden and Karin, 1997). SAPK, 
which are Jun N-terminal Kinases (JNK) and p38-kinases, are members of the Mitogen-
Activated Protein Kinase (MAPK) superfamily. JNK comprise three isoforms: JNK1, JNK2 
and JNK3. Activated by stress stimuli through a MAPK cascade, JNK translocates to the 
nucleus, phosphorylates Jun within its N-terminal transactivation domain (on Ser63 and 
Ser73 residues) and thereby enhances its transactivation potential. In addition to Jun, JNK 
can also phosphorylate Junb, Jund and Atf2 and potentiate their activity (Hess et al., 2004). 
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Furthermore, AP-1 can be regulated by interaction with other transcription factors and 
cofactors. For instance, the mutual interference between AP-1 and steroid hormone receptors, 
particularly the Glucocorticoid Receptor (GR), represents an example of protein-protein 
interaction based crosstalk. In this context, the anti-inflammatory and immunosuppressive 
activities of glucocorticoids are mediated, at least in part, by GR-mediated repression of AP-1 
activity (Herrlich and Ponta 1994). In addition to GR, many transcription factors (e.g. C/EBP, 
Ets, Gata, NFAT, NF-κB, Runx, Sp1 and others), transcriptional cofactors (e.g. p300/CBP, 
TAF1, Trip6 and others) and subunits of chromatin remodeling complexes (e.g. SWI/SNF 
and HDAC3) have been found to physically interact and modulate AP-1 activity, although in 
most cases, the exact mechanism of interaction between AP-1 and these proteins remains to 
be determined (Hess et al., 2004). 
3.1.3 Role of AP-1 in development 
Most of our knowledge on the function of AP-1 proteins in development was obtained from 
loss of function experiments using gene targeting in mice.  These analyses revealed that each 
AP-1 component has specific functions during embryogenesis and organogenesis. In addition, 
while Fos, Fosb, Jund are dispensable, Jun, Junb and Fra-1 are essential for embryonic 
development since complete ablation of these proteins in mice results in embryonic lethality 
(Jochum et al., 2001). 
Mice lacking Fos are viable and fertile but lack osteoclasts resulting in an osteopetrotic 
phenotype (Johnson et al., 1992; Wang et al., 1992). Mutant mice also show abnormalities of 
the hematopoietic system including extramedullary hematopoiesis and lymphopenia (Okada 
et al., 1994). 
Mice lacking Fosb develop normally (Brown et al., 1996; Gruda et al., 1996). However, adult 
Fosb -/- females display a profound nurturing defect that correlates with the absence of Fosb 
expression in a hypothalamic region critical for nurturing behavior (Brown et al., 1996). In 
addition, Kuroda and colleagues reported broader neurobehavioral dysfunctions in Fosb -/- 
mice, which may share the same underlying molecular mechanisms that are also responsible 
for the nurturing defect (Kuroda et al., 2008). 
Fra-1 inactivation results in embryonic lethality around day 10 of development due to defects 
in the placenta and the yolk sac (Schreiber et al., 2000). The development of Fra-1-deficient 
embryos can be rescued up to birth by providing wild-type extra-embryonic tissues upon 
generation of tetraploid chimeras. These rescued Fra-1 deficient pups display no 
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morphological abnormalities, suggesting that Fra-1 is dispensable for the development of the 
embryo (Schreiber et al., 2000).  
The mice lacking Fra-2 show severe growth retardation, appear runted, and die within a week 
after birth. So far it is unknown for which physiological functions Fra-2 is required to ensure 
post-natal survival (Eferl et al., 2007). 
Mice lacking Jun die between day 12.5 and 13.5 of embryonic development (Hilberg et al., 
1993; Johnson et al., 1993). Jun-deficient embryos show defects of the interventricular 
septum in the heart and incomplete separation of the aorta and the pulmonary artery, 
indicating that Jun is essential for the development of a normal cardiac outflow tract (Eferl et 
al., 1999). Mutant embryos also show abnormalities in the liver, which include areas of 
hemorrhaging and generalized edema as well as increased numbers of apoptotic hepatoblasts 
and hematopoietic cells (Eferl et al., 1999; Hilberg et al., 1993). However, these 
abnormalities are not intrinsic to the hematopoietic compartment since lethally irradiated 
mice can be reconstituted with Jun-deficient fetal liver cells (Eferl et al., 1999). 
Junb is also essential for embryonic development and Junb-deficient embryos die between 
day 8.5 and 10.0 of embryonic development due to vascular defects in the extra-embryonic 
tissues (Schorpp-Kistner et al., 1999). Junb in vivo and in vitro functions will be discussed in 
more details in a subsequent paragraph. 
Jund, finally, is dispensable for development. Yet, mutant males show impaired growth, 
hormone imbalance and age-dependant defects in reproduction due to impaired 
spermatogenesis (Thepot et al., 2000). In addition, Jund has been shown to be involved in 
muscle cell differentiation and function (Andreucci et al., 2002; Ricci et al., 2005) and to play 
a crucial role in T lymphocyte proliferation and T helper cell differentiation (Meixner et al., 
2004). 
3.1.4 Role of AP-1 in stress response and apoptosis 
The isolation of genetically modified cells from animals with ablated AP-1 subunits has 
contributed to the deciphering of individual functions of these subunits in controlling cell 
proliferation, differentiation, apoptosis and neoplastic transformation.  
AP-1 activity is greatly enhanced upon treatment of cells with genotoxic agents, implying 
that AP-1 target genes are involved in the cellular stress response, including DNA repair, 
induction of survival and initiation of the apoptotic program. AP-1 has a dual function in 
stress response: it can induce apoptosis in some cellular systems but is required for cell 
survival in others. Therefore, the role of AP-1 in apoptosis should be considered within the 
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context of a complex network of signaling pathways. Here, some findings are described 
exemplifying the complexity of AP-1 regulated mechanisms of cell death. 
Many studies have highlighted an important role for the extrinsic death receptor pathway 
mediated by JNK, Jun/AP-1 and FasL (also called CD95L), in the control of lymphoid, 
fibroblast and neuronal cell fate. JNK, activated by the MAPK cascade, phosphorylates Jun 
and results in enhanced transcription of target genes implicated in cellular stress-induced 
apoptosis. Whereas Jun is a potent activator of Fas, FasL and TNF-α transcription, Fos 
abrogates Jun-mediated activation of Fas as well as negatively regulates FasL expression 
through a transcriptional repressor element within the FasL promoter (Hess et al., 2004).  
Some reports demonstrate a fundamental pro-apoptotic role for JNK/Jun signaling in the 
stress-induced mitochondrial death pathway (Behrens et al., 1999; Palmada et al., 2002; 
Whitfield et al., 2001). Expression of a dominant-negative Jun mutant reduces expression of 
Bim, a BH3-only member of the Bcl-2 family of apoptosis regulators and inhibits 
mitochondrial cytochrome c release (Whitfield et al., 2001). The importance of a putative 
JNK–Jun/AP-1–Bim pathway in neuronal cell death control is underscored by pathologies 
associated with deregulated apoptosis, such as Alzheimer’s disease. Furthermore, analyses of 
cell cultures derived from sympathetic and cerebellar granular neurons revealed a clear 
dependency on JNK/Jun activity for stimulation of apoptosis upon growth factor withdrawal 
(Palmada et al., 2002; Whitfield et al., 2001). Finally, the subunit Junb appears to act pro-
apoptotic in myeloid cells, as shown in mice lacking Junb in the myeloid lineage that develop 
a myeloproliferative disease (Passegue et al., 2001; Passegue et al., 2004). 
In addition to the pro-apoptotic functions of AP-1, numerous experiments have demonstrated 
that AP-1 is also critically involved in survival signaling. For instance, Fos expression 
negatively correlates with increased neuronal cell death in the hippocampus during kainic-
acid-induced seizure, indicating an anti-apoptotic role for Fos in this scenario (Zhang et al., 
2002). Jun expression is needed to prevent apoptosis in fetal hepatocytes during mouse 
development (Behrens et al., 1999; Eferl et al., 1999; Hilberg et al., 1993). During liver tumor 
formation, Jun prevents apoptosis by antagonizing p53 activity, and this may contribute to the 
early stage of human hepatocellular carcinogenesis (Eferl and Wagner, 2003). Moreover, Jun 
regulates transcription of p53 in mouse fibroblasts and, thus, apoptosis (Schreiber et al., 
1999). Furthermore, enhanced apoptosis in the absence of Jun is also observed in 
keratinocytes and notochordal cells (Behrens et al., 2003; Zenz et al., 2003). In the case of 
keratinocytes, Jun regulates expression of EGFR and its ligand HB-EGF, which controls 
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keratinocyte proliferation and survival (Zenz et al., 2003). Finally, JNK activation can also 
signal pro cell survival. Davis and colleagues demonstrated that Jund promotes JNK-
stimulated survival after TNF treatment by collaborating with NF-κB to increase expression 
of anti-apoptotic genes such as the inhibitor of apoptosis IAP-2 (Lamb et al., 2003).  
3.1.5 Junb, a special member of the Jun family 
3.1.5.1 Transcriptional and post-translational regulation of Junb  
Junb is induced by a plethora of cellular stress signal and its transcriptional regulation is 
mediated by different regulatory elements located in the 5’ and 3’ regions flanking its coding 
sequence. The transcriptional induction of Junb in response to various mitogens is mediated 
by multiple Ets sites (Coffer et al., 1994), an IL-6 response element containing a STAT3 
binding site and a CRE-like site (Nakajima et al., 1993), a GC box, an inverted repeat 
element and a novel myeloid-specific IL-6 response element (IL-6RE) (Sjin et al., 1999) in 
the proximal promoter region. In addition, the regulation of Junb by v-src involves the CAAT 
and TATA box region (Apel et al., 1992). Growth factor-initiated signaling pathways induces 
Junb through a TRE, a SRE and two Ets-linked motifs located in a region around -1000 to -
2000 in the mouse Junb promoter (Phinney et al., 1996). By contrast, Pdgfb, serum, bFGF, 
phorbol ester and forskolin mediate Junb induction by a SRE and a CRE site located in the 3’ 
flanking region of Junb gene (Perez-Albuerne et al., 1993). Finally, recently, four NF-κB 
binding sites located downstream of the gene have been shown to mediate transcriptional 
induction of Junb in response to oxygen deprivation (Schmidt et al., 2007). 
Although much less is known about the regulation of Junb via post-translational mechanisms, 
there are some evidences of Junb phosphorylation and SUMOylation. Junb is phosphorylated 
by JNK in T cells at threonine residues 102 and 104 and this phosphorylation is important for 
synergy with c-Maf transcription factor and T helper cell differentiation (Li et al., 1999). In 
addition, three proline-flanked serine or threonine residues (Ser23, Thr150 and Ser186) are 
specifically phosphorylated by p34cdc2-cyclinB kinase in M and early G1 phase of the cell 
cycle, correlating with a decrease in Junb protein levels. These residues are not conserved in 
Jun or Jund and the phosphorylation may target the Junb protein for degradation (Bakiri et 
al., 2000). Recently, Farras et al. observed that Junb becomes phosphorylated by mid-/late G2 
phase, that this phosphorylation leads to proteasome-mediated degradation, and that this 
event is required for proper cell cycle progression (Farras et al., 2008). 
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Furthermore, Junb conjugation with small ubiquitin-like modifier (SUMO) on lysine 237 
plays a critical role in T cell activation. Indeed, SUMO modification regulates the ability of 
Junb to induce cytokine gene transcription (Garaude et al., 2008). 
3.1.5.2 In vitro and in vivo functions of Junb 
Junb has been first characterized as an inhibitor of Jun function following the observations 
that excess of Junb over Jun is sufficient to inhibit transactivation of AP-1 reporter genes by 
Jun. Furthermore, Junb alone fails to transactivate artificial reporter genes containing a single 
TRE. So far, the exact mechanism by which Junb represses transcription is unknown but two 
different models have been proposed. First, Jun and Junb may compete for the DNA binding 
site, since both proteins have a similar DNA binding affinity.  Secondly, Junb may form a 
heterodimer with Jun that has a lower transactivation potential than a Jun:Jun homodimer, 
thus,  resulting in a lower net AP-1 activity. Most interestingly, Junb appears to be as 
effective as Jun in transactivating reporter genes containing multiple AP-1 binding sites 
(Angel and Karin, 1991; Chiu et al., 1989). 
Recent analyses carried out with cells and mice deficient for Junb revealed that Junb is not 
only a repressor of Jun activity but is also required for the transcriptional activation of key 
target genes involved in cell cycle regulation, proliferation, differentiation, angiogenesis as 
well as skin and hematopoietic functions. Thus, both activator and repressor functions of 
Junb are required for proper cell function and proper development and physiology of mice. 
Junb deficiency results in embryonic lethality between day 8.5 and 10.0 of embryonic 
development due to defective feto-maternal interactions. Most importantly, in absence of 
Junb, gene expression and function in cells of extra-embryonic tissues, such as trophoblast 
giant cells, as well as endothelial cells of the yolk sac and placental cell types are affected 
(Schorpp-Kistner et al., 1999).  
Analysis of Junb-deficient MEFs revealed that Junb suppresses cell proliferation via its target 
gene p16/Ink4a during G1 to S phase transition of the cell cycle (Passegue and Wagner, 
2000), but also promotes cell cycle progression from G2 to M phase via the transcriptional 
activation of cyclin A (Andrecht et al., 2002). Furthermore, recent data showed that the Junb 
breakdown in mid-/late G2 phase is required for down-regulation of cyclin A2 levels and for 
proper mitosis (Farras et al., 2008). 
Loss of Junb in conditional mutants with either a widespread deletion of Junb in various 
tissues or even a tissue-specific deletion in epidermis results in a myeloproliferative disease 
resembling human Chronic Myeloid Leukemia (CML) (Meixner et al., 2008; Passegue et al., 
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2001; Passegue et al., 2004). Detailed analyses revealed that Junb inactivation results in CML 
by specifically expanding the number of Long Term Hematopoietic Stem Cells (LT-HSC) 
and Granulocyte/Macrophage Progenitors (GMP) (Passegue et al., 2004). Also in humans, 
loss of Junb due to epigenetic promoter silencing could be associated with CML (Yang et al., 
2003), while Junb overexpression has been associated with cutaneous CD30-positive T-cell 
lymphomas (Rassidakis et al., 2005).  
In addition, Junb plays a critical role in bone biology by being responsible for the 
differentiation and proper function of chondrocytes and osteoblasts (Hess et al., 2003; Kenner 
et al., 2004). 
Furthermore, Junb is a critical regulator of the cutaneous response to injury or stress of the 
skin as shown by in vitro organotypic cultures (Szabowski et al., 2000) and conditional 
mouse mutants. Mice lacking Junb in the skin develop normally, indicating that Junb is 
neither required for cutaneous organogenesis nor homeostasis (Florin et al., 2006). Yet, in 
wounded skin, Junb-deficiency results in delayed tissue remodeling, pronounced epidermal 
hyperproliferation, disturbed differentiation and prolonged inflammation. These phenotypic 
skin abnormalities were associated with Junb-dependent alterations in expression levels and 
kinetics of cytokines governing wound repair, such as Csf2, Gro-1, Mip-2 and Lcn-2 in both 
the dermal and epidermal compartments of the skin, and with a reduced ability of wound 
contraction of mutant dermal fibroblasts in vitro (Florin et al., 2006). Moreover, inducible 
epidermal deletion of Junb and Jun in adult mice leads to a phenotype resembling the 
histological and molecular hallmarks of psoriasis, including arthritic lesions (Zenz et al., 
2005). Presumably, loss of Junb in keratinocytes triggers chemokine/cytokine expression 
resulting in the recruitment of inflammatory immune cells contributing to the psoriasis-like 
phenotype. Finally, epidermal Junb-deficiency causes skin ulcerations, myeloproliferative 
disease and low bone mass due to high systemic levels of the negatively regulated Junb-target 
G-CSF (Meixner et al., 2008). 
Junb has also an essential role in the differentiation and function of immune cells. Junb is 
involved in the differentiation of naïve T cells into T helper 1 and T helper 2 cells, which is a 
hallmark of the T cell-dependent immune response (Hartenstein et al., 2002). In addition, 
Junb regulates the ability of Natural Killer cells to kill target cells by regulation of NKG2D-
ligand Rae-1epsilon (Nausch et al., 2006). Finally, Junb is a critical regulator of mast cell 
biology. Junb is required for proper mast cell degranulation and for mast cell mediated-
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angiogenic processes, by regulating the expression of Swap70, Vamp8, Syt1 and Vegfa genes, 
respectively (Textor et al., 2007). 
The most dramatic consequences of loss of Junb are seen in the vascular system. Complete as 
well as endothelial-specific ablation of Junb result in a similar phenotype affecting the 
remodeling of the primary vascular plexus in the yolk sac of the developing embryo but also 
affecting angiogenic remodeling in the embryo itself (Licht et al., 2006; Schorpp-Kistner et 
al., 1999). A mechanistic explanation for the observed phenotypes could be provided: Junb is 
a target gene of hypoxia-induced signaling mediated by NF-κB and this occurs independently 
of the known master regulator of hypoxia-induced signaling Hypoxia-Induced Factor (HIF). 
Most importantly, in vitro analyses revealed that Junb is required for the expression and 
induction of the key regulator of angiogenesis Vegfa upon hypoxia and hypoglycemia 
(Schmidt et al., 2007; Textor et al., 2006). Thus, Junb is a critical independent regulator of 
the autocrine and paracrine acting Vegfa. In line with these findings, loss of Junb affects 
tumor angiogenesis due to impaired paracrine acting Vegf.  Junb is also required for proper 
endothelial cell morphogenesis both in vivo and in vitro in a cell-autonomous manner as 
shown by endothelial cell-specific ablation of Junb. In endothelial cells, Junb is required for 
Cbfb induction in response to hypoxia and subsequently for the expression of the Cbfb and 
AP-1 target Mmp13 (Licht et al., 2006). In summary, positively regulated Junb targets are 
required for proper vascular development.  Yet, negative regulation of cytokines by Junb is 
also of unequivocal importance to suppress a pro-inflammatory and pro-cancerogenic 
phenotype.  
3.2 Mechanisms of repression 
Gene repression, which is the process of keeping genes in an off state until transcription 
becomes activated as final step in signal transduction pathways, plays a central role in gene 
regulation. Indeed, it controls proper gene activation throughout development as well in 
response to extracellular signals (Courey and Jia, 2001). In fact, impaired gene repression due 
to aberrant expression of repressor proteins results in diseases, such as Rett (mutation of 
MeCP2 gene) and ICF syndromes (Immunodeficiency, Centromere instability and Facial 
anomalies syndrome, mutation of dnmt3b gene) as well as some human cancers. These 
findings underscores that transcriptional repression and gene silencing is essential for the 
maintenance of the cellular integrity of higher organisms (Thiel et al., 2004). 
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Eukaryotic transcriptional repression mechanisms are remarkably variable in their modes of 
action and effects. Some mechanisms are readily reversible, but others establish a heritable 
state of long-term silencing (Moazed, 2001). Three different mechanisms are described. First, 
repression can act directly on the transcription initiation complex. It has been shown that 
blockade of the targeting of TATA-binding proteins to the TATA box on the DNA or 
inhibition of the formation of the initiation complex of RNA polymerase II result in gene 
repression (Pugh, 2000). Secondly, a factor can repress gene expression indirectly by 
inhibiting an activating component located on the promoter. Such repression can be mediated 
either by protein-protein interaction and subsequent inhibition of the transactivation activity 
or by competition for a transcription factor binding site at the promoter of the gene (Cowell, 
1994). Third, repression can be achieved by active remodeling of the chromatin structure 
through epigenetic modifications.  
As described in the previous section of this work, Junb, due to its weak transactivation 
domain, is considered as an inhibitor of AP-1, in particular of Jun. Thus, by forming weakly 
active dimers with Jun, Junb absorbs the activity of AP-1 and acts as a repressor (Chiu et al., 
1989). In this work, I wanted to investigate the ability of Junb to repress genes independently 
of its weak transactivation activity and to determine whether Junb, in addition, acts as an 
active repressor by modulating the chromatin structure. 
3.2.1 Epigenetics 
3.2.1.1 Definition 
Epigenetics is the study of heritable alterations in phenotype and gene expression acquired 
during development and cellular differentiation that are not caused by a modification in the 
DNA sequence. Epigenetic changes are orchestrated by four different mechanisms: chromatin 
modifications, DNA methylation, non-coding RNAs as well as nucleosome repositioning.  
Much of epigenetic studies converged on the analyses of covalent and non-covalent 
modifications of DNA and histones. Therefore, these two mechanisms, chromatin 
modifications and DNA methylation, will be described in more detail in the following 
paragraphs. 
3.2.1.2 Histone modifications 
In the nuclei of all eukaryotic cells, the double stranded DNA is highly folded and tightly 
compacted by histone and non-histone proteins in a dynamic three dimensional structure 
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called chromatin. The chromatin organization is dependent on a higher order structure, 
namely nucleosomes. The nucleosome, which is wrapped by two superhelical turns of DNA 
and 147 base pairs in length, represents the basic repeating unit of chromatin and is composed 
of eight histones: one H3-H4 tetramer and two H2A-H2B dimers (Luger et al., 1997). 
Histones are small basic proteins which consist of a globular domain and a flexible basic N-
terminal tail that protrudes from the nucleosome. N-terminal histone tails are subjected to 
many covalent modifications which control and modify the DNA binding properties of 
nucleosomes. At least 8 different modifications have been described so far and include 
acetylation, lysine and arginine methylation, phosphorylation, ubiquitination, sumoylation, 
ADP ribosylation and others. In addition, histones can be modified on as many as 60 
residues. The complexity is further increased by the fact that some modifications such as 
methylation can occur in different forms. For instance, lysines are mono-, di- and tri-
methylated while arginines are mono- and di-methylated, symmetrically or asymmetrically. 
Thus, this wide amount of possible modifications provides an enormous potential and ensures 
a very fine tuning of functional responses (Kouzarides, 2007).  
Whereas most of the modifications are still poorly understood, much effort has been brought 
about the understanding of the function and regulation of histone acetylation and methylation. 
On the one hand, histone acetylation almost always correlates with chromatin accessibility 
and transcriptional activity. It is achieved by both relaxation of the DNA backbone following 
the neutralization of positive charge of the N-terminal histone tail and by recruitment of 
enzymes. For instance, acetylated histones recruit the bromodomains of nucleosome 
remodeling complexes, which, under ATP expenditure, displace nucleosomes and open the 
chromatin (Syntichaki et al., 2000). 
On the other hand, methylation can have different functions depending on which residue is 
modified. While histone H3 methylation on lysine 4 (H3K4) and 36 (H3K36) is associated 
with transcribed chromatin, H3 methylation on lysine 9 (H3K9), 27 (H3K27) and H4 
methylation on lysine 20 (H4K20) correlate with repression. In contrast to histone 
acetylation, transcriptional regulation by lysine methylation is always achieved through 
recruitment of chromatin modifying enzymes. For example, methylated H3K4 recruits, via 
the chromodomain of Chd1, transcription activating complexes (Pray-Grant et al., 2005), 
while methylated H3K9 or H3K27 binds HP1 and Polycomb proteins, respectively, and 
mediate chromatin compaction (Bannister et al., 2001). 
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Furthermore, while most of the covalent modifications are associated with changes in 
transcription, few of them, such as acetylation, methylation, phosphorylation and 
ubiquitination, have also been involved in other DNA processes such as DNA repair, 
replication and condensation (Kouzarides, 2007). 
3.2.1.3 Histone modifying enzymes and HDACs 
In the past years, much effort has been invested to characterize histone modifying enzymes. 
Enzymes, which catalyze acetylation (Sterner and Berger, 2000), methylation (Zhang and 
Reinberg, 2001), phosphorylation (Nowak and Corces, 2004), ubiquitination (Shilatifard, 
2006), sumoylation (Nathan et al., 2006), ADP-ribosylation (Hassa et al., 2006) and others, 
have been identified. Since most modifications have been found to be dynamic, in addition, 
enzymes have been discovered that remove all previously described modifications, except for 
arginine demethylases.  
Among these enzymes, histone deacetylases (HDACs) attracted particular interest. Indeed, 
HDACs play global roles in the regulation of gene transcription, cell growth, survival and 
proliferation and alterations in HDACs expression or activity have been intensively 
correlated to disease state such as cancer (Cress and Seto, 2000). 
HDACs consist of three different classes based on their homology to yeast counterparts. 
While the class I, composed of HDAC1, 2, 3 and 8, are homologue to RbAp48 (Rb-
associated protein 48), the class II, HDA-1 like proteins, comprises at least 6 homologues in 
vertebrates: HDAC4, 5, 6, 7, 9 and 10. The class III, which do not share any homology with 
the classes I and II, is composed of NAD+ dependent deacetylases called sirtuins (SIR1-7).  
HDACs are tightly regulated through a multitude of mechanisms, such as recruitment into co-
repressor complexes, modulation of deacetylase activity by protein-protein interactions or 
post-translational modifications as well as translocation from the cytoplasm to the nucleus 
(Yang and Seto, 2008b).   
All class I members, with the exception of HDAC8, function as catalytic subunits of mSin3, 
NuRD (nucleosome remodeling deacetylase), SMRT (silencing mediator of retinoic acid and 
thyroid hormone receptors) and CoREST (corepressor of RE1-silencing  transcription factor) 
co-repressor complexes (Yang and Seto, 2008b). HDACs do not have the ability to bind 
directly to DNA, but, by being part of co-repressor complexes, they get to interact with DNA 
sequence specific factors and repress transcription as well as shape epigenetic patterns. In 
mammals, two mSin3 co-repressor complexes exist: mSin3A and mSin3B. More precisely, 
mSin3A is composed of many different proteins, including HDAC1, 2, and ING2. By binding 
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to methylated histone H3 on lysine 4, ING2 targets the whole complex to deacetylate regions 
of the genome where H3K4 is methylated (Ahringer, 2000). 
Class II members are characterized by tissue-specific expression and can exist both in the 
nucleus and in the cytoplasm. They contain intrinsic nuclear import and export signals for 
dynamic nucleo-cytoplasmic trafficking. Therefore, association of partners (such as 14-3-3) 
upon diverse signaling stimuli controls both the subcellular distribution and the repression 
activity of HDACs (Yang and Seto, 2008b). 
Additionally, although implicated in deacetylation of the histone H4 on lysine 16, recently, 
sirtuins became of great interest in the scientific community, since they have been described 
to promote longevity both in yeast and mice and, therefore, to be protective against aging and 
neurodegenerative disease (Saunders and Verdin, 2007; Vaquero et al., 2007). 
Finally, protein acetylation became accepted as a post-translational modification capable of 
regulating protein activity, localization, protein-protein interaction as well as other 
mechanisms and the list of acetylated proteins increased in the past years (Yang and Seto, 
2008a). There is accumulating evidence that HDACs deacetylate those non histone proteins 
as well. For instance, HDAC6 controls, in addition to gene expression, multiple cellular 
processes by deacetylating tubulin as well as hsp90 (Kovacs et al., 2005; Zhang et al., 2008; 
Zhang et al., 2003).  
3.2.1.4 DNA methylation 
DNA methylation occurs almost exclusively in the context of CpG dinucleotides in 
vertebrates and most of the CpG dinucleotides in the genome are methylated (Bird, 2002). 
Non-CpG methylation has an established function in plants (Chan et al., 2005) and may play 
a yet-to-be defined role in mammals as well. 
Mammalian DNA methylation has been implicated in a broad range of cellular functions and 
diseases, including tissue-specific gene expression, cell differentiation, genomic imprinting, 
X chromosome inactivation, regulation of chromatin structure, genomic stability, 
carcinogenesis and aging (Bird, 2002). It is essential for proper development (Li et al., 1992; 
Okano et al., 1999) and remains indispensable for the survival of differentiated cells 
(Jackson-Grusby et al., 2001).  
Mechanistically, methylated cytosine residues regulate gene expression by the fact that they 
can promote or exclude the recruitment of regulatory proteins (Bernstein et al., 2007). On the 
one hand, methyl-CpG binding proteins bind to methylated CpG dinucleotides and mediate 
transcriptional repression through interactions with co-repressor complexes and HDACs. A 
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family of five methyl-CpG binding proteins (MBD1, 2, 3, MeCP2 and Kaiso) has been 
characterized and each member contains a region closely related to the Methyl-CpG Binding 
Domain (MBD) of MeCP2 (Bird, 2002). On the other hand, the methylation on cytosine 
residues can exclude DNA binding proteins from their DNA consensus sequence. It has been 
described, for example, for CTCF binding at the H19 locus and will be further explained in 
the next paragraph. 
DNA methylation patterns are dynamic during development. Shortly after fertilization, in 
mammals, the paternal genome is actively demethylated, while the maternal genome 
presumably undergoes passive demethylation. Genome-wide methylation levels increase 
rapidly in the blastocyst and eventually result in the formation of methylation patterns found 
in the adult (Reik et al., 2001).  Although the molecular determinants responsible for the 
patterning of de novo methylation in the blastocyst remain mysterious, de novo methylation is 
achieved by the two DNA Methyltransferases DNMT 3a and 3b. Then, once the methylation 
patterns are set, the DNA methyltransferase 1 (DNMT1) maintains the methylation patterns 
between cell divisions by residing in the replication fork and having a higher affinity for 
hemi-methylated DNA.  
Finally, alterations in DNA methylation are observed in patho-physiology such as cancer. 
Indeed, in tumorigenesis, the methylome undergoes characteristic changes with genome-wide 
loss of methylation and genome instability, as well as aberrant local gain of methylation on 
promoters of tumor suppressor genes. These findings underscore that genetics and epigenetics 
cooperate at all stages of cancer development (Jones and Baylin, 2002, 2007). 
3.2.1.5 Imprinting  
Genomic imprinting is an epigenetic mechanism of transcriptional regulation through which 
expression of a subset of mammalian genes is restricted to one parental allele. While either 
the maternal or paternal allele is expressed, the other is silenced. Imprinting has been found 
only in mammals and not in other vertebrates. 
The importance of imprinting in development and growth have been underscored by the fact 
that embryos generated from a monoparental genome fail to develop (Solter, 1988), as well as 
by  development of cancers and disease syndromes following loss of imprinting (Prader-
Willi, Angelman and Beckwith-Wiedemann syndromes) (Nicholls and Knepper, 2001; 
Weksberg et al., 2005). A common feature of imprinted genes is the control of fetal 
development by paternally expressed genes, such as Igf2, and maternally expressed genes, 
such as H19 and Igf2r, that positively and negatively regulate growth, respectively. 
  3. Introduction 
24 
 
To date, around 70 genes have been shown to be controlled by imprinting. A majority of 
them are arranged in clusters in the genome and this organization appears to be required for 
appropriate gene regulation (Verona et al., 2003). Such clusters are often composed of 
multiple protein coding genes and at least one non-coding region RNA and they are regulated 
by a major cis-acting element, called Imprinting Control Region (ICR). The ICR acquires 
differential epigenetic modifications such as DNA methylation and histone modifications 
during gametogenesis, which are subsequently retained during development (Reik et al., 
2001). 
3.2.1.5.1 H19 
H19 and Igf2 (insulin-like growth factor 2) genes were among the first imprinted genes 
identified in the mouse. Both genes are also imprinted in humans and many aspects of the 
regulation identified in mice also apply to humans. 
The H19 gene encodes a 2.3 kb non-coding mRNA which is strongly expressed during 
embryogenesis. So far, the function of H19 has not been deciphered. Mice carrying deletions 
of the H19 gene are viable and fertile. Although such mutations lead to an overgrowth 
phenotype, the molecular cause has been linked to a loss of imprinting of the adjacent Igf2 
gene. Furthermore, recent work from Cai X and Cullen B identified H19 as a micro RNA 
precursor (miR-675) but further analyses are still required to uncover miR-675 target genes 
and functions (Cai and Cullen, 2007). 
The H19-igf2 locus, located within a conserved imprinted cluster on mouse chromosome 7 
and human chromosome 11p15, contains the maternally expressed H19 and the paternally 
expressed Igf2 gene. The imprinting mechanism of H19 has been widely studied. First, both 
genes, H19 and Igf2, share a common enhancer located 10 kb downstream of H19 
transcriptional start (Yoo-Warren et al., 1988). Second, the 90 kb segment located between 
H19 and Igf2 genes defines a region where many different regulatory elements have been 
identified using targeted germ line deletion and transgenic approaches in the mouse (Sasaki et 
al., 2000). More precisely, the analyses of this cluster revealed an essential 2kb ICR that is 
differentially methylated. The paternally methylated region, also called Differentially 
Methylated Domain (DMD), is located 4kb upstream of the H19 gene. This region is, indeed, 
essential since its deletion by genetic manipulation leads to a loss of expression of H19 
(Brannan and Bartolomei, 1999; Sasaki et al., 2000). The ICR domain contains four binding 
sites for the CCCTC binding factor (CTCF) included in CpG rich elements.  
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CTCF binding is crucial for the control of differential expression of H19 between maternal 
and paternal alleles as well as for the establishment and the maintenance of differential 
methylation and imprinting of H19. First, CTCF is involved in insulator activity, meaning 
CTCF can block the interaction between enhancers and promoters. On the maternally 
inherited allele, CTCF binds to the unmethylated DMD, creating a chromatin insulator which 
prevents the Igf2 promoter from gaining access to the downstream enhancers. On the 
paternally inherited allele, the DMD is methylated, which blocks CTCF binding. This lack of 
CTCF binding inactivates the insulator, allowing the promoter of the paternal Igf2 allele to 
interact with the downstream enhancers and, thus, to be transcribed (Bell and Felsenfeld, 
2000; Hark et al., 2000). Secondly, in addition to the fact that CTCF binding is sensitive 
towards methylation, the DNA methylation itself is dependent on CTCF binding. Indeed, 
mutation of the CTCF binding site in the DMD results in increased methylation of the 
maternally inherited gene in post-implantation development (Pant et al., 2003; Schoenherr et 
al., 2003). Similar results have been obtained upon use of siRNA-mediated knock down of 
CTCF in the oocyte, which results in increased H19 DMD methylation (Fedoriw et al., 2004).  
3.3 Stress responses 
As described above, AP-1 plays multiple roles in stress responses and stress-induced 
apoptosis being either pro-apoptotic or anti-apoptotic, depending on the balance of AP-1 
members in the given cell, the cell lineage, the differentiation stage, the microenvironment 
and the type of stimulus (Hess et al., 2004). Previous work based on in vivo mouse models as 
well as in vitro tissue culture models derived thereof defined a crucial role for Junb in cellular 
hypoxia and hypoglycemia responses (Schmidt et al., 2007; Textor et al., 2006). Recent 
evidence has emerged that hypoxia and hypoglycemia may trigger ER stress that may act as 
an important contributor to hypoxia tolerance and tumor progression. Due to the facts that 
AP-1 is a key player in many stress responses and that so far a link between AP-1 and ER 
stress response is still missing, I aimed to decipher the implication of Junb in the ER stress 
response but also in stress-induced apoptosis.  
3.3.1 Unfolded protein response (UPR) 
In eukaryotic cells, secreted and transmembrane proteins fold and mature in the lumen of the 
endoplasmic reticulum (ER). The flux of proteins entering into the ER depends on multiple 
factors such as cell differentiation, environmental conditions and physiological state of the 
cell. Cells adjust the protein-folding capacity of the ER according to their requirements in 
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order to maintain the high quality of transmembrane and secreted proteins. An imbalance 
between the load of protein entering the ER and the folding capacity of the ER induces a 
condition of stress, called ER stress. ER stress activates an adaptive response, namely 
unfolded protein response or UPR, which will act in three steps. First, the cell reduces the 
protein load entering the ER by lowering protein synthesis and translocation into the ER. 
Second, in order to increase the capacity of the ER to handle unfolded proteins, the cell 
transcriptionally activates UPR target genes implicated in the protein folding machinery. 
Third, if the cell does not re-establish homoeostasis, programmed cell death is triggered (Ron 
and Walter, 2007). 
ER stress has been defined as an initiating and/or contributing factor in a broad range of age-
related diseases, including neurodegeneration (Ryu et al., 2002), tumor development (Bi et 
al., 2005; Koumenis, 2006) and type 2 diabetes (Ozcan et al., 2004; Ozcan et al., 2006).  
As shown in Figure 1, ER stress is controlled by a unique ER-located chaperone, namely 
Grp78 (78kDa glucose-related protein, also BiP or Hspa5). While, under resting state, Grp78 
binds to and, therefore, inhibits the downstream initiators of the UPR, misfolded protein 
accumulation displaces Grp78 and activates UPR (Bertolotti et al., 2000). Three ER stress 
transducers have been identified and each of them regulates a distinct arm of the UPR: PERK 
(protein kinase RNA (PKR)-like ER kinase), IRE1 (inositol requiring kinase 1) and ATF6 
(activating transcription factor-6) (Szegezdi et al., 2006). Active PERK phosphorylates the 
eukaryotic Initiating Factor 2 α (eIF2α or Eif2a) and triggers global attenuation of protein 
synthesis as well as cell cycle arrest (Harding et al., 2000b). In addition, phosphorylated 
eIF2α selectively translates mRNAs transcripts, such as Atf4 (activating transcription factor 
4), which has been described to induce the expression of the pro-apoptotic transcription factor 
CHOP (CAAT/Enhancer binding protein homologous protein, Gadd153 or Ddit3) (Harding 
et al., 2000a). IRE1 (or Ern2), which is a serine, threonine protein kinase and an 
endonuclease, initiates the unconventional splicing of the transcription factor Xbp1 mRNA 
transcript (X-box binding protein 1). Spliced Xbp1 is subsequently translated and gives rise 
to a transcription factor activating the expression of numerous genes involved in the UPR, 
such as grp78, grp94 and chop (Calfon et al., 2002). Finally, upon dissociation of Grp78, 
ATF6 is processed by the site-1 and -2 proteases S1P and S2P (or Mbtps1 and Mbtps2, 
respectively) in the Golgi and subsequently translocates to the nucleus, where it activates the 
expression of key players of the UPR (Ye et al., 2000). 
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3.3.2 Prolonged ER stress will result in mitochondria-mediated apoptosis 
Upon prolonged misfolded protein load in the ER, PERK, ATF6 and IRE1 signaling will 
induce cell death. These signaling pathways do not directly cause apoptosis but rather initiate 
the activation of downstream molecules, which subsequently trigger the cell to the path of 
death.  
As shown in Figure 2, all pathways inducing apoptosis converge on the activation of 
caspases. Caspases are cysteine-aspartic acid proteases that coordinate the efficient 
destruction of the cell by cleavage of multiple substrates and activation of DNases. Two 
pathways of programmed cell death can be distinguished (Fig. 2). The so-called extrinsic or 
death-receptor mediated pathway is triggered by the death receptors (members of the Tumor 
Necrosis Factor (TNF) receptor family such as Fas, also named CD95, or TNF receptor-1). 
Upon binding of the ligand, the receptor recruits and activates caspase-8, which results in the 
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subsequent activation of downstream effector caspases without any involvement of the 
mitochondria and the Bcl-2 family members. The second pathway, targeting mitochondrial 
functionality is called intrinsic pathway. Since prolonged ER stress has been described to 
induce apoptosis through the intrinsic pathway (Szegezdi et al., 2006), this mechanism will 
be described in more detail in the following section (Fig. 2). 
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In addition to supply energy to the whole cell by generation of adenosine triphosphate (ATP), 
the mitochondria play a central role in many processes such as cell signaling, differentiation, 
growth and apoptosis. Most apoptosis-inducing conditions involve the disruption of the 
mitochondrial transmembrane potential which results in a sudden increase of mitochondria 
membrane permeability. Thus, osmotic swelling will eventually lead to the rupture of the 
outer membrane and to the release of pro-apoptotic proteins, such as cytochrome C, from the 
mitochondria into the cytoplasm (Loeffler and Kroemer, 2000). Those mitochondrial events 
are kept under strict control by the Bcl-2 family members, which will be further discussed in 
the next paragraph. 
Bcl-2 family members, which are key regulators of the intrinsic apoptosis pathway, have 
been described by homology to the structure of the original Bcl-2 (B-cell lymphoma-2) 
protein. The family comprises, in mammals, at least 12 members that have been grouped into 
three classes. One class inhibits apoptosis (Bcl-2, Bcl-xL, Mcl1 and others), whereas a 
second class promotes apoptosis (Bax, Bak and others). The third class, composed of BH3-
only proteins (Bad, Bid, Bim, Bmf, Noxa, Puma and others), have a conserved BH3 domain 
that binds and regulates the anti-apoptotic Bcl-2 family members, thereby promoting 
apoptosis (Youle and Strasser, 2008; Zha et al., 1996). There are clear evidences that the pro-
apoptotic members Bax and Bak are crucial for inducing permeabilization of the outer 
mitochondrial membrane, by forming oligomeres which resemble pores (Saito et al., 2000; 
Schlesinger et al., 1997). Yet, the biochemical nature of these pores remains unknown and 
controversial. Anti-apoptotic members, such as Bcl-2 and Bcl-xL, inhibit the formation of 
oligomeres by direct binding to Bax and Bak and, thus, hinder the formation of pores in the 
outer mitochondrial membrane and subsequent caspase activation (Sedlak et al., 1995). 
Once the outer mitochondrial membrane is permeabilized, proteins including cytochrome c 
are released into the cytosol. Then, cytochrome c forms with APAF-1 a heptameric protein 
ring called apoptosome, which binds to pro-caspase-9 and induces its activation through a 
conformational change (Shi, 2006). Active caspase-9 will eventually result in activation of 
the effector caspase-3 and subsequent cell death (Hakem et al., 1998). 
The molecular mechanisms involved in the death of ER stressed cells remain poorly 
understood and many different models have been proposed, which involve diverse essential 
molecules, such as Bcl-2 family members, CHOP, SAPK/JNK, and caspase-12.  
Bcl-2 family members have been shown to be essential for ER stress-mediated apoptosis. 
Indeed, Bax and Bak ablation in MEFs result in resistance towards ER stress and treatment 
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with other stress stimuli known to activate the intrinsic apoptosis pathway, including growth 
factor retrieval, ultraviolet (UV) irradiation, staurosporine and etoposide (Wei et al., 2001). In 
addition, an imbalance in expression of pro-apoptotic and anti-apoptotic Bcl-2 family 
members with excess of anti-apoptotic protein levels results in decreased cell death following 
ER stress induction (Szegezdi et al., 2006). Although the involvement of Bcl-2 proteins in ER 
stress-mediated apoptosis is well known, their regulation by UPR is less understood. So far 
two different mechanisms have been described.  First, CHOP, a pro-apoptotic transcription 
factor induced upon PERK activation, has been shown to negatively regulate Bcl-2 gene 
expression. Indeed, overexpression of CHOP results in induction of apoptosis due to low Bcl-
2 expression and re-expression of Bcl-2 in these cells could efficiently block CHOP-induced 
apoptosis (McCullough et al., 2001). Secondly, induction and post-translational modifications 
of BH3-only proteins by JNK has been reported as key event in the ER stress-mediated 
apoptosis cascade. JNK is activated by a protein complex formed by activated IRE1 which 
contains the adaptor protein TRAF2 and the MAPK Kinase ASK1 (Urano et al., 2000). JNK-
triggered phosphorylation of Bim releases Bim from an inhibitory association with the dynein 
motor complex and, thus, allows Bim to exert its pro-apoptotic effects (Lei and Davis, 2003). 
In addition, JNK promotes Bax translocation to the mitochondria through phosphorylation of 
14-3-3, a cytoplasmic anchor of Bax (Tsuruta et al., 2004).  
Finally, caspase-12 has been proposed as a key mediator of ER stress-induced apoptosis. 
Caspase12 -/- MEFs have been reported to exhibit partial resistance specifically against ER-
stress inducing agents (Nakagawa et al., 2000). However, in a recent work published by Saleh 
and colleagues, Caspase12 -/- MEFs, originated from another source, displayed no resistance 
to ER stress mediating agents (Saleh et al., 2006). In addition, only a few consistent data 
linking caspase-12 to downstream caspase activation is available, thus, it is difficult to state 
an essential role for this caspase in ER-stress induced apoptosis (Szegezdi et al., 2006). 
                         4. Aims 
32 
 
4 Aims 
During my thesis work, I addressed two scientific problems associated with the in vivo 
functions of Junb that are still not yet solved but that may be of fundamental importance with 
regard to the double-edge role of Junb in cancer: the function of Junb as a negative 
transcriptional regulator and its impact in the ER stress response and apoptosis.   
The analysis of global gene expression between wild-type and Junb knock-out mouse 
embryonic fibroblasts revealed a big set of genes derepressed in absence of Junb. It was 
claimed that Junb, by being a weak transactivator, on its own may act as a repressor by 
forming less active heterodimers with other AP-1 subunits and, thus, absorbing the Jun and 
other AP-1 members’ activity. In this work, I investigated the repressor activity of Junb and 
wanted to decipher other possible repression mechanisms. Therefore, during my PhD work, I 
aimed to answer these two questions. 
1. Does Junb modulate the acetylation-deacetylation status of genes by regulating the 
expression of HDACs and/or members of co-repressor complexes? 
2. Does Junb regulate methylation of promoters and/or imprinted domains? 
Previous work based on in vivo mouse models as well as in vitro tissue culture models 
derived thereof defined a crucial role for Junb in cellular hypoxia and hypoglycemia 
responses. Recent evidence has emerged that hypoxia and hypoglycemia may trigger ER 
stress and UPR. Since UPR controls protein synthesis, cell metabolism, cell cycle progression 
and cell death, it may act as an important contributor to hypoxia tolerance and tumor 
progression. Although AP-1 is a key player in many stress responses and stress-induced 
apoptosis, so far a link between AP-1 and ER stress response is still missing. Therefore, I 
studied the implication of Junb in the ER stress response but also in stress-induced apoptosis 
in order to answer the following questions: 
1. Is Junb induced upon ER stress? And is the UPR deregulated in absence of Junb? 
2. Does loss of Junb affect ER stress-mediated apoptosis? And if so what are the 
molecular mechanisms responsible for the observed phenotype? 
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5 Material and methods 
5.1 Material 
5.1.1 Chemicals 
Acrylamid/Bisacrylamid (30:0,8)    Roth, Karlsruhe 
Agarose      Sigma, Deisenhofen 
Ammoniumperoxodisulfat (APS)    Janssen Chimica 
Ampicillin       Sigma, Deisenhofen 
Bacto agar       Roth, Karlsruhe 
Bacto tryptone      Gerbu Biotechnik, Gaiberg 
Bacto yeast extracts      Gerbu Biotechnik, Gaiberg 
β-Mercaptoethanol      Merck, Darmstadt  
Bismaleimidohexane (BMH)    Pierce 
Bovine serum albumine, fraction V    Sigma, Deisenhofen 
Bromphenol blue      Serva, Heidelberg 
Calcium chloride      Merck, Darmstadt 
DC protein measurment kit    Biorad, Munich 
Dithiothreitol (DTT)      AppliChem, Darmstadt 
DMSO (Dimethylsulfoxide)     Merck, Darmstadt 
EDTA (Ethylenediamine-tetraacetate)   Roth, Karlsruhe 
EGTA        Roth, Karlsruhe 
Entellan       Merck, Darmstadt 
Eosin B       Sigma, Deisenhofen 
Enhanced chemiluminescent system   Perkin Elmer, Waltham, USA 
Ethanol       Sigma, Deisenhofen  
Ethanolamine       Merck, Darmstadt 
Ethidium bromide      AppliChem, Darmstadt 
Fugene      Roche, Mannheim 
HEPES       Gerbu Biotechnik, Gaiberg 
Hoechst H33342     Calbiochem, Darmstadt 
Isopropanol      Sigma, Deisenhofen 
Kanamycin      Sigma , Deisenhofen 
Mayer’s hematoxylin      Roth, Karlsruhe 
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Methanol       Sigma , Deisenhofen 
Milk powder      Roth, Karlsruhe 
MitoTracker
® 
CMXRos     Invitrogen, Karlsruhe 
Mowiol      Calbiochem, Darmstadt 
Nitrocellulose-Membran     Schleicher und Schuell, Dassel 
Positively charged nylon membrane   GE healthcare, Munich 
Paraformaldehyde      Roth, Karlsruhe  
Polybrene       Sigma, Deisenhofen 
Proteinase K      Merck, Darmstadt 
Puromycin      Sigma, Deisenhofen 
Saccharose      Merck, Darmstadt 
SDS       Gerbu Biotechnik, Gaiberg 
TEMED       Roth, Karlsruhe 
Triton X-100      AppliChem, Darmstadt 
Tween 20       Sigma, Deisenhofen  
Xylol       Merck, Darmstadt 
Xylencyanol       Serva, Heidelberg 
 
All other chemicals not listed here were either from Merck, Sigma or Roth. 
5.1.2 Enzymes and molecular biology reagents 
AnnexinV APC     BD Biosciences, Heidelberg 
dNTP       Promega, Mannheim 
OligodT      Fermentas, St-Leon-Rot 
Restriction enzymes Promega, Fermentas, New England 
Biolabs 
Revertaid M-MuLV Reverse Transcriptase  Fermentas, St-Leon-Rot 
Riboblock RNase inhibitor    Fermentas, St-Leon-Rot 
RQ1 DNase RNase-free    Promega, Mannheim  
SYBR green fluorescein    Thermo Scientific 
T4 DNA ligase     Promega, Mannheim 
Taq polymerase     Genaxxon, Steinbrenner 
Thermosensitive Alcaline Phosphatase  Promega, Mannheim 
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Gene ruler 100bp DNA ladder   Fermentas, St-Leon-Rot 
Gene ruler DNA ladder mix    Fermentas, St-Leon-Rot 
Protein marker IV     Peqlab Biotechnology, Erlangen 
5.1.3 Equipment 
Bacterial petri dishes      Greiner, Frickenhausen 
Cell culture articles      TPP, Trasadingen, Switzerland  
Cell incubator      Heraeus, Hanau 
Centrifuge       Heraeus, Hanau 
Centrifuge J2-HS with rotors JS-13.1 and JA-1  Beckman, Munich 
Electrophoresis chambers    Cosmo bio, Carlsbad, USA 
ELISA reader      Biorad, Munich 
Gel documentation     Peqlab Biotechnology, Erlangen  
FACS Calibur      Becton Dickinson, Heidelberg 
Leica microscope      Leica, Bensheim 
Microtome RM 2155      Leica, Bensheim 
PCR Cycler       BioRad, Munich 
Plastic tubes       TPP, Trasadingen, Switzerland 
Reaction Tubes      Steinbrenner Laborsystem, Wiesenbach 
SDS-PAGE chambers     Sigma, Deisenhofen 
Slides        Bender and Hohbein, Karlsruhe 
Nanodrop Spectrophotometer    PeqLab Biotechnology, Erlangen 
UV-Stratalinker 2400     Stratagene, Heidelberg 
Wet blotting transfer system    Sigma, Deisenhofen 
Whatman 3MM paper     Schleicher und Schuell, Dassel 
5.1.4 Oligonucleotides 
5.1.4.1 RT-PCR oligonucleotides  
Junb  
primers for qRT-PCR 
• RT2 qPCR primer assay – SYBR Green Mouse Junb: PPM03821A, SuperArray 
HPRT 
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Name Sequence 5’-3’ 
hprt-F GCATTTAAAAGGAACTGTTGACAACG 
hprt-R TTGTTGGATTTGAAATTCCAGACAAG 
 
ER-located chaperones 
Name Sequence 5’-3’ 
grp78-F AGGACATCAAGTTCTTGCCATT 
grp78-R AATAGTGCCAGCATCTTTGGTT 
grp94-F TCAGAGACATGTTGCGGCGGATTA 
grp94-R TTCTGCGTCTTCTGAGGTGTCTTC 
calnexin-F AGGGGAGGTTTATTTTGCTGAC 
calnexin-R CATGATGCTTGGCCCGAGACA 
 
XBP1 splicing 
Name Sequence 5’-3’ 
mXBP1.19S GGCCTTGTGGTTGAGAACCAGGAG 
mXBP1.14AS GAATGCCCAAAAGGATATCAGACT 
 
Mitochondria-mediated apoptosis  
Name Sequence 5’-3’ 
clusterin-F GAAGTTCTATGCACGTGTCTGC 
clusterin-R TCCTGAAAGAGCGTGTCTATGA 
 
Growth factors 
Name Sequence 5’-3’ 
Pdgfa-F AGCCGGCCGCCCCTCTCC 
Pdgfa-R TTTTGTGGTTTTGTTTTCGCTCTC 
Pdgfb-F AGCAGAGCCTGCTGTAATCG 
Pdgfb-R GGCTTCTTTCGCACAATCTC 
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Pdgfralpha-F CTGGGAAAGTGGCCTGGACGAAC 
Pdgfralpha-R ACGCCGCTGAGATGCTACTGACG 
Pdgfrbeta-F CTGCGCTGGACCTGCTATGAGAC 
Pdgfrbeta-R TGGTGACAGTGGCCCGAGGTAAC 
gmcsf-F ATCAAAGAAGCCCTAAACCTCCTG 
gmcsf-R CTGGCCTGGGCTTCCTCATT 
csf2ra-F ATGTTTAACGACATTGATGTCACC 
csf2ra-R GGGTTAGGGTTTGTTAAGAACTGA 
csf2rb-F GTCAAGCCCATCTCTAACTACGAT 
csf2rb-R GATCTTTTCCTTCCACTTCCTGTA 
csf2rb2-R ATTGCATCATTTCTCCACCTATTT 
csf2rb2-R CAGTGAACATAGACCAAGGAACAC 
kgf-F CTGGCCTTGTCACGACCTGTTTCT 
kgf-R -CCCTTTCACTTTGCCTCGTTTGTC 
 
Epigenetics 
Name Sequence 5’-3’ 
dnmt1-F CCACTGCATTTGCTGAATACAT 
dnmt1-R TGGTAGAAGGAGGAACAGTGGT 
dnmt3b-F GATGGCTTTCTTTTACCCTCCT 
dnmt3b-R AATAGCATCCTCCAGCAAATGT 
ctcf-F ACTTGCGAAAGCAGCATTCC 
ctcf -R TGTCTTGCCATTGTGTTCCG 
 
Junb target genes 
Name Sequence 5’-3’ 
lpl-F TTGAAAGTGGGTTTTCCTGAGT 
lpl-R CTCCTGCCTGCTGTCTTCTAAT 
decorin-F GAACCTGAAGGACTTGCATACC 
decorin-R CAAGCACATTGTTCAGTCCATT 
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gsta4-F GAGAAGATGCAAAAGGATGGAC 
gsta4-R TCCTGACTCTCTCCTTCAGGTC 
cyba-F CGATGTGGACAGAAGTACCTGA 
cyba-R CTGCCAGCAGATAGATCACACT 
wdr79-F CCTGATGGCAATCTCTTCTTCT 
wdr79-R TCCACTGATATCCCACACAGAG 
epb4.1l4b-F GACGGACGGAATATCAAGCTAC 
epb4.1l4b-R ATTGTGGACTTCAGGATTTGCT 
slc35e3-F AAGACACACCCCTAGGTCTCAA 
slc35e3-R ACATTTAGTGAGGCCAGGAAAA 
fas-F AAAGTGCTGGAAAAGGAGACAG 
fas-R TCTTGCCCTCCTTGATGTTATT 
h19-F GGGGACTTCTTTAAGTCCGTCT 
h19-R GGGTGCTATGAGTCTGCTCTTT 
mkp1-F AACTCGGCACATTCGGGACCAA 
mkp1-R CAAGCGAAGAAACTGCCTCAAACA 
id1-F GCCCCAGAACCGCAAAGTGA 
id1-R TTAACCCCCTCCCCAAAGTCTCTG 
id3-F GGTGCGGCTGCTACGAG 
id3-R TTCAGGCCACCCAAGTTCAGTCC 
 
5.1.4.2 Non radioactive EMSA oligonucleotides 
 
Name transcription 
factor site 
Origin of 
binding site 
sequence 5'-3' 
PDGF-wt-F AP-1, ets1. 
NFAT 
PDGFb AGCTGCGCTGACTCCGGGC
CAGGAGAGGAAAGGCTGA
GCT 
PDGF-wt-R AP-1, ets1. 
NFAT 
PDGFb AGCTCAGCCTTTCCTCTCCT
GGCCCGGAGTCAGCGCAGC
T 
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MMP13-TRE-F AP-1 MMP13 AGCTAAAGTGGTGACTCAT
CACTATAGCT 
MMP13-TRE-R AP-1 MMP13 AGCTATAGTGATGAGTCAC
CACTTTAGCT 
consensus-SP-1-F SP-1  ATTCGATCGGGGCGGGGCG
AGC 
consensus -SP-1-R SP-1  GCTCGCCCCGCCCCGATCG
AAT 
PDGF-SP1-F SP-1 PDGFb AGCTTGTCTCCACCCACCTC
TCAGCT 
PDGF-SP1-R SP-1 PDGFb AGCTGAGAGGTGGGTGGAG
ACAAGCT 
PDGF-TRE-F AP-1 PDGFb AGCTTAGGGTGAATCACAG
AAGGAAGCT 
PDGF-TRE-R AP-1 PDGFb AGCTTCCTTCTGTGATTCAC
CCTAAGCT 
PDGFbwt-Ets1-F ets1 PDGFb AGCTCCAGGAGAGGAAAG
GCTGAGCT 
PDGFbwt-Ets1-R ets1 PDGFb AGCTCAGCCTTTCCTCTCCT
GGAGCT 
Ets-F ets1 stromyelosin1 AGCTGCAGGAAGCATTTCC
TGGAGCT 
Ets-R ets1 stromyelosin1 AGCTCCAGGAAATGCTTCC
TGCAGCT 
 
5.1.5 shRNA 
shRNA against mouse clusterin cloned into the lentivirus vector pLK0.1-puro were purchased 
from Sigma-Aldrich. 
Name Sequence 5’-3’ and region targeted by the shRNA 
shRNA1    CCGGCCGGTTTATATGATCTTCATACTCGAGTATGAAGATC
ATATAAACCGGTTTTTG 
Region: CDS 
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shRNA2 CCGGCCTGAAACAGACCTGCATGAACTCGAGTTCATGCAG
GTCTGTTTCAGGTTTTTG 
Region: CDS 
shRNA4 CCGGGCTAAAGTCCTACCAGTGGAACTCGAGTTCCACTGGT
AGGACTTTAGCTTTTTG 
Region: CDS 
shRNA5 CCGGAGGGAAGTAAGTACGTCAATACTCGAGTATTGACGT
ACTTACTTCCCTTTTTTG 
Region: CDS 
Non-targeting 
shRNA 
Catalogue number: SHC002 
 
5.1.6 Antibodies 
Name Company Catalogue number 
Junb (N17) Santa Cruz Biotechnology Sc-46 
 
ER-stress proteins 
Name Company Catalogue number 
Grp78 Cell Signaling Technology 3177 
CHOP Santa Cruz Biotechnology Sc-575 
p-eIF2a Cell Signaling Technology 9725 
eIF2a Upstate ab5369 
 
Mitochondria-mediated apoptosis 
Name Company Catalogue number 
Caspase 3 Cell Signaling Technology 9662 
Caspase 6 Cell Signaling Technology 9762 
Caspase 9 Cell Signaling Technology 9504 
Cleaved PARP (Asp214) Cell Signaling Technology 9544 
Bax Cell Signaling Technology 2772 
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Bak Cell Signaling Technology 3814 
Bcl2  Cell Signaling Technology 2870 
Bcl-XL Cell Signaling Technology 2762 
Bad Cell Signaling Technology 9292 
p-Bad S112 Cell Signaling Technology 9296 
p-Bad S136 Cell Signaling Technology 9295 
Clusterin Santa Cruz Biotechnology Sc-6419 
Cytochrome c Promega G7421 
 
MAPK pathway and growth factor signaling 
Name Company Catalogue number 
p-ERK1,2 Cell Signaling Technology 9101 
ERK1,2 Cell Signaling Technology 4696 
p-JNK (T183/Y185) Cell Signaling Technology 9251 
JNK1 Santa Cruz Biotechnology Sc-1648 
JNK2 Santa Cruz Biotechnology Sc-7345 
p-Akt S473 Cell Signaling Technology 4051 
Akt Cell Signaling Technology 9272 
p-PDGFRa Y754 Cell Signaling Technology 2992 
PDGFRa Cell Signaling Technology 3164 
p-PDGFRb Y751 Cell Signaling Technology 3166 
PDGFRb Cell Signaling Technology 3169 
 
Epigenetic mediators 
Name Company Catalogue number 
HDAC 1 Cell Signaling Technology 2062 
HDAC 2  Upstate 05-814 
HDAC 3 Cell Signaling Technology 2632 
HDAC 5 Cell Signaling Technology 2082 
HDAC 6 Cell Signaling Technology 2162 
HDAC 7 Cell Signaling Technology 2882 
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MeCP2 Upstate 07-013 
mSin3A Santa Cruz Biotechnology Sc-994 
CTCF Upstate 07-729 
 
Name Company Catalogue number 
HSC70 Stressgen SPA-816 
Actin  Santa Cruz Biotechnology Sc-1615 
RCC1 BD biosciences 610377 
 
Secondary antibodies 
Name Company Catalogue number 
Anti-mouse HRP-
conjugated Cell Signaling Technology 7076 
Anti-rabbit HRP-conjugated Cell Signaling Technology 7074 
Anti-goat HRP-conjugated Santa Cruz Biotechnology Sc-2020 
 
5.1.7 Inhibitors 
• N-glycosylation inhibitor 
o Tunicamycin, Sigma 
• PI3-Kinase inhibitor 
o Wortmannin, Sigma  
o LY294002, Calbiochem  
• Proteasome inhibitor 
o MG132, Sigma 
• RNA polymerase II inhibitor 
o Actinomycin D, Sigma 
• HDAC inhibitors 
o Trichostatin A, Sigma 
o Sodium Butyrate, Sigma 
• Protease inhibitor 
o Sigma 
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• Phosphatase inhibitors 
o Phosphatase inhibitor cocktail I, Sigma 
o Phosphatase inhibitor cocktail II, Sigma 
5.1.8 Kits 
• RNA extraction kit: RNeasy, Qiagen 
• Genomic DNA extraction kit: blood and tissue extraction kit, Qiagen 
• Plasmid purification kit: PureLink HiPure plasmid maxi kit, Invitrogen 
• PCR purification kit, Qiagen 
• Gel extraction kit, Qiagen 
• Bisulfite treatment of genomic DNA: EpiTect Bisulfite kit, Qiagen 
• LightShift Chemiluminescent EMSA kit, Pierce 
• Dual luciferase assay system, Promega 
• Mycoplasma PCR detection kit, PromoKine 
5.1.9 Bacterial culture  
• Bacteria strains used : 
o E.Coli DH5 alpha, 
o TOPO-10 (Invitrogen) 
• TY medium composition: 1% Bacto-tryptone, 1% Bacto yeast extract, 0,1% 
Casamino acids, 5% NaCl 
• Solid medium contains 2% (w/v) Agar 
• Ampicillin: 100µg/ml, 
• Kanamycin: 50µg/ml 
5.1.10 General buffer and solutions 
• PBS: 137 mM NaCl, 2.7 mM KCl, 6.5 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.6 
• TBE: 90 mM Tris-HCl, 90 mM Boric acid, 2.5 mM EDTA 
• SDS running buffer: 25mM TrisBase, 250mM Glycine, 0.1% SDS 
• TE: 10 mM Tris-HCl pH 8.0, 1 mM EDTA 
• 10x DNA loading buffer: 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol 
FF, 30% (v/v) glycerol 
• Laemmli sample buffer: SDS 2%, glycerol 10%, 50mM Tris pH 6.8, 5% b-
mercaptoethanol, bromophenol blue 
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5.1.11 Cell culture  
5.1.11.1 Cell types 
• Mouse embryonic fibroblasts (MEFs) were isolated at embryonic day 8.5 and 
immortalized using the 3T3 protocol 
o Wild-type: clones 1, 7, 47 
o Junb -/-  MEFs: clones 6, 10, 49 
• HEK293T cells 
• Phoenix ecotropic packaging cells: Orbigen, San Diego, USA 
5.1.11.2 Cell culture material 
DMEM (Dulbecco Modified Earle’s Medium) high glucose  PAA, Pasching, Austria 
Trypsin 2.5% (10x)        Lonza, Wuppertal 
Fetal bovine serum       Sigma, Deisenhofen 
Penicillin/streptomycin      PAA, Pasching, Austria 
L-Glutamine 200mM (100x)      PAA, Pasching, Austria 
Cell culture petri dishes      TPP, Trasadingen, CH 
5.1.12 Animals 
Mice were housed in specific pathogen free and light, temperature (21°C), and humidity 
(50%-60% relative humidity) controlled conditions. Food and water were available ad 
libitum. The procedures for performing animal experiments were in accordance with the 
principles and guidelines of the ATBW (officials for animal welfare) and were approved by 
the Regierungspräsidium Karlsruhe. 
5.2 Methods 
5.2.1 Bacterial methods 
5.2.1.1 Transformation 
Competent bacteria were incubated on ice with plasmid DNA (50-100ng) for 30 min, heat 
shocked at 42°C for 90 seconds and then replaced on ice for 2 min. After adding 1 ml of TY 
medium, the bacteria were incubated 1h at 37°C with shaking. Transformed bacteria were 
then further selected on a TY-Agar plate containing the appropriate antibiotics. 
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5.2.2 DNA methods 
5.2.2.1 Plasmid mini-preparation and maxi-preparation 
Transformed bacteria were grown overnight in 3 ml (mini-preparation) or 200 ml (maxi-
preparation) of TY-medium supplemented with the appropriate antibiotics.  For plasmid 
mini-preparation, bacteria were resuspended and lysed in the solution provided with the 
purification kit from Invitrogen. The DNA was further precipitated with 2.5 volumes of 
100% EtOH (-20°C), washed with 1 volume 70% EtOH and resuspended in H2O. For maxi-
preparation, plasmid DNA was extracted with the purification kit from Invitrogen following 
the instruction of the manufacturer. DNA was resuspended in H2O. Purity and concentration 
were measured with a NanoDrop spectrophotometer. 
5.2.2.2 Isolation of genomic DNA 
Genomic DNA from tissues was extracted using the following procedure. The tissue was 
digested in 500µl tail buffer (50mM Tris-HCl pH 8.0, 100mM NaCl, 100mM EDTA, 1% 
SDS) supplemented with 250µg of Proteinase K overnight at 56°C. Proteins were precipitated 
with 250µl 5M NaCl. Then, the DNA in the supernatant was precipitated with 0.67 volume of 
isopropanol, washed with 70% EtOH and resuspended in TE buffer. 
For the analysis of DNA methylation, genomic DNA was extracted using the DNA blood and 
tissue extraction kit from Qiagen following the instructions of the manufacturer. 
5.2.2.3 Cloning and sub-cloning 
In order to clone a promoter region or a coding sequence, primers containing the restriction 
site of interest were designed. The PCR fragment was subsequently sub-cloned into the 
pGEMT-easy (Promega) or TOPO-pCR4 (Invitrogen) vectors and its sequence was 
confirmed by sequencing (MWG Biotech). 1 μg of the vector was digested with 3 units of the 
adequate restriction enzyme in the recommended buffer and further isolated by 
electrophoresis. The separated fragment of DNA was then isolated with the Gel extraction 
and Purification Kit from Qiagen following the instructions. Equimolar amounts of insert and 
vector (minimum 100ng) were ligated overnight at 4°C with 3 unit of T4 ligase following the 
instruction of the company.  
5.2.2.4 PCR 
A standard PCR reaction was performed as follows: 
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• 10-500 ng template DNA 
• 2.5 μl 10 x PCR buffer recommended by the Taq provider 
•  1 μl 25mM dNTP solution (containing dATP; dCTP; dGTP; dTTP; pH 7.0) 
• 0.2 μl of each primer (0.1 μg/μl or 10μM) 
• 1 U Taq polymerase 
• H20 to 25 μl 
DNA was initially denatured for 5 min at 95°C. PCR was carried out with 20-40 cycles for 
each 30 sec at 95°C; 30 sec at the appropriate annealing temperature and 0.5-1.5 min 
extension at 72°C, depending on the length of DNA fragment to amplify. 
5.2.3 RNA methods 
5.2.3.1 RNA isolation 
RNA was isolated from cultured cells with the RNeasy kit from Qiagen following the 
instruction of the manufacturer. RNA from tissues was extracted in PeqLab Gold RNA pure 
followed by a second purification over the columns of the RNeasy easy kit from Qiagen. 
Purity and concentration were measured with a NanoDrop spectrophotometer. 
5.2.3.2 DNase digestion of RNA 
In order to avoid genomic DNA contamination, 5 μg of RNA were digested with 1 unit of 
RQ1 RNase-free DNase for 30 min at 37°C in a final volume of 20 μl. RQ1 digested RNA 
was then purified following a phenol-chloroform extraction. In brief, 1/10 volume of 3M 
NaOAc (pH 5.2), one volume of phenol and one volume of chloroform:isoamyl alcohol 
(49:1) were added and mixed well. The mixture was centrifugated at 13 000 rpm at room 
temperature for 5 min. The upper phase containing the DNA was carefully taken and 
precipitated with 2.5 volumes of 100% ice-cold ethanol. After 2 h incubation at -20°C, the 
mixture was centrifugated at 4°C at 13 000 rpm for 30min. The supernatant was removed and 
the pellet washed with 70% ethanol. After another centrifugation, the pellet was dried and 
resuspended in RNase-free H2O. 
5.2.3.3 Reverse Transcriptase PCR (RT-PCR) 
5 μg of RQ1-digested RNA was reverse transcribed into cDNA as follows 
• 5 μg of RQ1-digested RNA denatured at 70°C for 5 min 
• 1 μl of oligo-dT primers 
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• 10 μl of 5x reverse transcriptase buffer 
• 2 μl of 25mM dNTP solution 
• 2 μl of RNase inhibitors (Riboblock) 
• 1 μl of reverse transcriptase 
• In a final volume of 50 μl 
The reaction was incubated at 42°C for 1 h followed by 10 min at 70°C in order to inactivate 
the reverse transcriptase. cDNA was further diluted and used for semi-quantitative or 
quantitative PCR. The amplified products were then analyzed on an agarose gel. 
5.2.3.4 Quantitative RT-PCR 
Relative quantification of PCR products was assessed as follows: PCR amplification was 
done in triplicates in a final volume of 25 μl by using a SYBR green mix. Primer efficiency 
was measured for each PCR run, by including dilution series of a reference cDNA. The 
primer efficiency was incorporated into the calculation of the fold induction as indicated 
hereafter. 
  
5.2.4 Protein methods 
5.2.4.1 Cell extracts 
5.2.4.1.1 Whole cell extracts 
Cells were washed twice with PBS and lysed in RIPA (50mM Tris pH 8.0, 150mM NaCl, 
0.1% SDS, 0.5% deoxycolic acid, 1% Nonidet P-40, 2mM DTT) or Cell Lysis buffer (Cell 
Signaling Technology). After 30 min incubation on ice, the extracts were briefly sonicated 
(2.5 min in a Bioruptor sonicator with an ON/OFF cycle of 30 sec / 20 sec) and centrifugated 
20 min at 13’000 rpm at 4°C. The supernatant was collected and kept at -80°C. 
5.2.4.1.2 Nuclear extracts 
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Cells were washed twice with PBS and collected in hypotonic buffer (20mM HEPES, 10mM 
KCl, 1mM MgCl2, 0.5mM DTT, 0.1% Triton X-100, 20% glycerol supplemented with 
proteases and phosphatases inhibitors). The cell membranes were destroyed by 18 strokes 
with a douncer.  After centrifugation at 2’000 g for 5 min at 4°C, the supernatant containing 
the cytoplasmic fraction was collected. The pelleted nuclei were further lysed in extraction 
buffer (20mM HEPES, 10mM KCl, 1mM MgCl2, 0.5mM DTT, 0.1% Triton X-100, 20% 
glycerol, 420mM NaCl supplemented with proteases and phosphatases inhibitors) and 
nuclear membranes were destroyed by performing 5 freeze and thaw cycles. Debris were then 
removed by another centrifugation step at 13’000 rpm. The supernatant was collected and 
kept at -80°C. 
In order to obtain nuclear extracts from animal tissues, the samples were pulverized by using 
a dismembrator. The powder was then resuspended in hypotonic buffer and the samples were 
processed as described before. 
5.2.4.1.3 CHAPS extracts 
Cells were washed twice with PBS and lysed in CHAPS buffer (Cell Signaling Technology). 
After 30 min incubation on ice, three freeze and thaw cycles were performed. The extracts 
were centrifugated 20 min at 13’000 rpm at 4C. The supernatant was collected and kept at -
80°C. 
5.2.4.1.4 Mitochondria extracts and Bax oligomerization 
Cells were washed twice with PBS and lysed in hypotonic buffer (250mM sucrose, 20mM 
HEPES pH7.5, 10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, supplemented with 
proteases and phosphatases inhibitors). The cytoplasmic fraction was incubated with 5mM 
Bismaleimidohexane (BMH) for 30min at RT or with DMSO. The cytoplasmic fraction was 
further centrifuged and the pellet, containing the mitochondrial fraction, was lysed into 
Laemmli buffer and boiled at 95°C for 5 minutes. 
5.2.4.1.5 Protein concentration determination 
The protein concentration of the samples was measured with the DC protein measurement kit 
from Biorad. 
5.2.4.2 Western Blotting 
20 to 50 μg of proteins were denatured into Laemmli sample buffer and boiled at 95°C for 5 
min. Denatured protein were separated on a SDS-polyacrylamide gel (SDS-PAGE). Proteins 
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were transferred onto a nitrocellulose membrane overnight in a wet blotting system (25mM 
Glycine, 0.15% Ethanolamine, 25% MetOH) by application of 69 V. The membrane was then 
blocked against unspecific signal by incubation in 5% milk or BSA in PBS/0.1% Tween-20. 
The first antibody was incubated overnight at 4°C, and then the membrane was washed 3 
times with PBS/0.1% Tween-20 and incubated for an hour with the secondary antibody. After 
3 additional washes with PBS/0.1% Tween-20, the signal was revealed with an enhanced 
chemiluminescence system. 
5.2.4.3 Luciferase 
48 h after transfection cells were lysed in luciferase extraction buffer (100mM K-phosphate 
pH 7.6, 0.2% Triton X-100, and 1mM DTT) and incubated 15 min at room temperature. 
Measurement of luciferase activity was performed with the dual luciferase reporter assay 
system from Promega following the instructions of the manufacturer. 
5.2.4.4 Electrophoretic Mobility Shift Assay (EMSA) 
Non radioactive EMSA were performed according to the LightShift Chemiluminescent kit 
from Pierce. In brief, 5µg of nuclear extracts were incubated in binding buffer with 50ng 
polydI.dC and competitor DNA (unlabelled oligonucleotides) for 10 min at RT. 20 fmoles of 
5’ biotinylated primers encompassing the transcription binding site of interest were then 
added to the mixture and incubated 20 further min at RT. Each transcription factor requires a 
special binding buffer related to its biochemical properties. For AP-1, the binding buffer is 
composed of 10mM Tris pH 7.5, 50mM KCl, 10% glycerol, 5mM MgCl2, 0.5mM EDTA, 
2mM DTT. For SP-1, the binding buffer is composed of 10mM Tris pH 7.5, 150mM KCl, 
15% glycerol, 0.1 % NP-40, 15mM MgCl2, 0.1µM ZnCl2, 1mM DTT. 
After incubation 20 min at RT, the complex was loaded on a 4% polyacrylamide gel 
previously pre-run for 1h. Migration was performed at 200V for 1h30 in 0.25% TBE buffer. 
Then, the probes were transferred in a wet blotting system in 0.5% TBE buffer at 500mA for 
1h30 at 4°C. The DNA was further cross linked on the membrane by application of 
1200µJoules in a UV cross linker. Detection of shifted probes was made by using a 
chemiluminescent system with streptavidin-HRP according to the manufacturer’s 
instructions. 
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5.2.5 Epigenetics methods 
5.2.5.1 Isolation of histones 
Cells were washed twice with PBS and lysed in hypotonic buffer (20mM HEPES, 10mM 
KCl, 1mM MgCl2, 0.5mM DTT, 0.1% Triton X-100, 20% glycerol supplemented with 
proteases, phosphates and HDAC inhibitors). Cells were disrupted by 18 strokes in a dounce 
homogenizer. The lysate was centrifugated at 2’000g for 5 min at 4°C and the supernatant 
transferred to another tube. The nuclear pellet was washed twice with hypotonic buffer and 
resuspended in 100 μl ice-cold H2O. Sulfhydric acid (H2SO4) was added to a final 
concentration of 0.4N. After 1 hour incubation on ice, the sample was centrifugated at 13’000 
rpm for 15 min at 4°C. The proteins of the supernatant including the histones were 
precipitated with 10 volumes acetone by overnight incubation at -20°C. After centrifugation 
at 13’000 rpm for 15 min at 4°C, the pellet was air dried and resuspended in H2O. The purity 
of the histone preparation was assessed by SDS-PAGE followed by a Coomassie staining. 
5.2.5.2 DNA methylation analysis: Combined Bisulphite Restriction Analysis 
(COBRA) and bisulphite sequencing 
The bisulfite treatment of 2 μg of genomic DNA was performed with the EpiTect Bisulfite 
Kit from Qiagen following the instructions of the manufacturer. PCR amplification of the 
regions of interest was performed with PCR primers recognizing bisulfite converted DNA 
sequences. The primers were designed with the Methprimer software. 
For COBRA analysis, the PCR fragments were digested with the restriction enzyme BstUI 
following the instruction of the provider. The fragments were separated by gel 
electrophoresis.   
For bisulfite sequencing, the PCR fragments were cloned into the TOPO-pCR4 vector and 
sequencing of 5 to 10 mini-preparations of DNA were analyzed. 
5.2.6 Immunoflorescence methods 
5.2.6.1 Mitotracker / Cytochrome c staining 
Cells, seeded on glass coverslips, were labeled in vivo 30 min with 200nM MitoTracker
®
, 
washed with PBS and fixed with 4% formaldehyde for 15 min. All steps were performed in 
the dark in order to avoid quenching of the fluorescent MitoTracker
®
dye. After 2 washes with 
PBS, cell membrane were permeabilized by incubation with 100% ice-cold Methanol at -
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20°C for 20 min. Cells were further washed three times with PBS and unspecific signal was 
blocked with 1%BSA/PBS supplemented with 0.2% Tween 20 for 1 h. Coverslips were 
washed with PBS and incubated with cytochrome c antibody (diluted 1:1000 in PBS 
supplemented with 0.3% Triton X-100) overnight at 4°C. After 3 washes with PBS, cells 
were incubated with the secondary antibody (Alexa488-conjugated goat anti mouse diluted 
1:500) and with Hoechst 33342 (diluted 1:1000) 1h at RT. After 3 additional washes, 
coverslip were mounted with mowiol on microscope slides. 
5.2.7 Cell culture 
5.2.7.1 Culture conditions 
Mouse embryonic fibroblasts (MEFs) cells were cultivated in high glucose DMEM 
supplemented with 4mM glutamine and 10% FBS and were maintained at 37°C and 8% CO2. 
Cells were trypsinised (0.25% Trypsin) three times a week. Mycoplasma tests (PromoKine 
mycoplasma PCR detection kit) were performed routinely. 
5.2.7.2 Co-culture conditions 
Cells were co-cultivated in a 0.4 µM filter insert (Falcon) placed above a six-well dish.  Cells 
were seeded in equal density and were allowed to grow for 48h. Dishes were carefully 
shacked every 6 to 10h to obtain a homogenous growth factor distribution. 
5.2.7.3 Transfection 
5.2.7.3.1 Calcium phosphate transfection 
50 μl of a solution of 1M of CaCl2 was added to the appropriate amount of plasmid DNA 
diluted into 500 μl of H2O. HBS 2x (50mM HEPES, 280mM NaCl, 1.5mM Na2HPO4, pH 
7.05) was added drop by drop to the mixture while vortexing. The mixture was incubated 15 
min in order to allow the calcium phosphate precipitate to form and subsequently added to a 
10 cm diameter dish with semi-confluent cells. The precipitate was left on the cells for 24 
hours, then the medium was replaced. 
5.2.7.3.2 Transfection with Fugene 
Plasmid DNA and Fugene were added to DMEM in a ratio of 1: 2.5. The mixture was 
incubated for 15 min at RT and added to semi-confluent cells. 24 h later, the medium was 
replaced with fresh medium. 
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5.2.7.4 Retroviral and lentiviral Transduction 
In order to produce retrovirus, a 10cm diameter dish of ecotropic Phoenix packaging cells 
was transfected with 25 μg of the vector of interest. One day after transfection, the medium 
was replaced by 6 ml of fresh medium. After 48h, the supernatant containing the virus 
particles was filtrated through a 0.45 μm filter and supplemented with 8μg/μl polybrene, 
before being added to the transduced cells. After 24h incubation, the cells were passaged and 
further analyzed. For lentivirus production, the same procedure was applied in HEK293T 
cells by co-transfection of plasmids encoding gag-pol (pMDLgrpRRE), VSV-g (pMD2-G) 
and Rev (pRSVrev). 
5.2.8 FACS analysis 
5.2.8.1 AnnexinV staining 
Cells, treated with different drugs for the appropriate time, were trypsinised and resuspended 
in 100 µl of AnnexinV buffer (10mM Hepes/NaOH pH 7.4, 150mM NaCl, 5mM KCl, 1mM 
MgCl2, 1.8 mM CaCl2). Cells were incubated with 2 µl AnnexinV APC for 30 min on ice in 
the dark, then washed and AnnexinV incorporation was measured by fluorescent activated 
cell sorting (FACS) with a FACS Calibur. 
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6 Results 
6.1 Junb as a positive and negative transcription regulator 
6.1.1 Analysis of histone H3 acetylation marks 
Gene activation has been correlated with an increased acetylation of the promoter region 
(Marushige, 1976). In order to investigate whether the observed gene de-repression in the 
absence of Junb is due to an increase in global histone acetylation, I analyzed the levels of 
acetylated histone H3 in wild-type and Junb-deficient cells. Therefore, I isolated histones 
from cells treated with Trichostatin A (TsA), a large spectrum HDAC inhibitor, or with 
vehicle (DMSO) and subsequently determined levels of acetylation on 3 different lysines 
(K9, K18 and K27) of the N terminal tail of histone H3 by immunoblot. As shown in Figure 
3, no significant increase in acetylation could be observed in unchallenged Junb-deficient 
MEFs when compared to wild-type cell. Treatment with TsA for 4 and 12h lead to similar 
increased levels of acetylation of histone H3 on the lysines 9, 18 and 27 for both wild-type 
and Junb -/- MEFs. Thus, loss of Junb does not result in a global hyperacetylation of histone 
H3. 
 
6.1.2 Analysis of HDACs expression 
Within the last years, it became clear that histone acetylation is also located outside of coding 
sequences and is very important for the stability of the genome (Kouzarides, 2007). Thus, 
promoter hyperacetylation of a subset of genes, namely the Junb targets, could not be 
detected on total histone extracts. Further analyses, such as the determination of expression 
levels of enzymes that remove histone acetylation, HDACs, would be required to monitor 
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global differences in acetylation distribution. In order to analyze whether an impaired 
expression of HDACs would be causative of the observed gene de-repression, we determined 
HDACs protein levels in wild-type and Junb-deficient MEFs. Immunoblot analysis of nuclear 
protein fractions revealed no difference in the expression and localization of HDACs 1, 2, 3, 
5, 6 and 7 between wild-type and Junb-deficient MEFs (Fig. 4).  
Since HDACs require co-repressor complexes to be targeted to promoter regions, I also 
measured protein levels and localization of the co-repressor complexes mSin3A and MeCP2 
by immunoblotting. Similar mSin3A levels were observed for wild-type and Junb-deficient 
MEFs (Fig. 4). Protein expression and localization of MeCP2, that binds to methylated CpGs 
and targets HDACs to DNA methylated promoter regions, was also not altered in Junb-
deficient MEFs when compared to wild-type cells  (Fig. 4). 
 
In conclusion, levels of HDACs, mSin3A and MeCP2 are unaffected in Junb-deficient MEFs. 
6.1.3 Analysis of transcription induction by HDAC inhibition 
Although, no apparent differences in HDACs, mSin3A and MeCP2 levels were detected, it 
still may be feasible that the promoters of previously identified Junb repressed genes were 
regulated by HDACs. In order to prove that, I measured by qRT-PCR the induction of Junb-
repressed mRNA transcripts in response to HDAC inhibition. In order to avoid any unspecific 
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effects of HDAC inhibitors, MEFs were treated with two different inhibitors covering a broad 
spectrum of HDACs: TsA and Sodium Butyrate (NaB). 
MEFs were treated for 24h with TsA (100nM) and NaB (10mM) applying doses that induce 
similar levels of H3 acetylation (H3K9Ac; Fig. 5A). Immunoblot analysis of nuclear extracts 
revealed that Junb is not induced upon 24h treatment with TsA and NaB (Fig. 5B). 
 
Then, MEFs were subjected to the HDAC inhibitor treatments as described and RNA was 
extracted. qRT-PCR was performed for all Junb-repressed target genes which have been 
identified in previous transcription profiling arrays (Florin et al., 2004). Four different classes 
of genes could be identified. First, I could identify genes induced by both HDAC inhibitors in 
wild-type as well as in Junb-deficient MEFs (Fig. 6). This class comprised the following 
genes: lipoprotein lipase (lpl), clusterin (clu), mapk phosphatase 1 (mkp1), SUMO1 
activating enzyme subunit 2 (sae2) as well as solute carrier family 35 member E3 (slc35e3).  
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Secondly, I could define genes that were only induced in wild-type MEFs (Fig. 7). These 
genes were encoding for glutathione S-transferase alpha 4 (gsta4), erythrocyte protein band 
4.1-like 4b (epb4.1l4b) and inhibitor of DNA binding 1 (id1).  
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Furthermore, expression of many genes did not change upon treatment with TsA or NaB (Fig. 
8A). These genes were 78 kDa glucose-regulated protein (grp78), decorin, cytochrome b-245 
alpha polypeptide (cyba), WD repeat domain 79 (wdr79) as well as Fas. Finally, the 
expression of few genes such as inhibitor of DNA binding 3 (id3) and keratinocyte growth 
factor (kgf) was decreased due to TsA and NaB treatments (Fig. 8B).  
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Taken together, this approach identified a subset of Junb-target genes that are regulated by 
HDACs in wild-type and Junb knock-out MEFs. Among those genes, gsta4, epb4.1l4b and 
id1 are of particular interest since they are induced by HDAC inhibitors only in wild-type 
cells, suggesting that these genes may be regulated through yet to be identified Junb-
dependent HDACs mechanism. 
6.1.4 H19, a novel Junb target gene 
The H19 transcript has been identified as the most highly up-regulated gene in Junb-deficient 
MEFs by previous transcription profiling array (Florin et al., 2004). This could be validated 
by semi-quantitative RT-PCR (Fig. 9A) demonstrating that H19 transcripts were highly 
increased in Junb -/- cells. De-repression was truly Junb-dependent as re-expression of Junb in 
null cell upon retroviral transduction reduced H19 transcripts to levels observed in wild-type 
cells. This confirms that H19 is a novel Junb-target gene. 
 
In order to investigate whether an impaired expression of H19 regulators may be causative 
for the enhanced transcript levels of H19 in Junb-deficient MEFs, I analyzed the expression 
of dnmt1, dnmt3a and ctcf by RT-PCR. Yet, wild-type and Junb-deficient MEFs expressed 
dnmt1, dnmt3a and ctcf transcripts at similar levels (Fig. 9B). In line with these findings, 
                                                                                                                                       6. Results 
59 
 
CTCF protein levels were also unaffected in Junb-deficient MEFs as shown by immunoblot 
of nuclear extracts (Fig. 9C), while the expression of DNMT1 and DNMT3a proteins could 
not be detected by immunoblot, most likely due to very low expression levels (data not 
shown). Thus, Junb regulates H19 transcription but not the expression of factors involved in 
the setting and maintenance of the imprinting status of this gene. 
6.1.5 Junb regulates the methylation of the H19 imprinting domain 
Since CTCF binds only to its unmethylated DNA recognition sequence, loss of methylation 
of the imprinting domain of H19 would increase the binding of CTCF, enhance the activity of 
the downstream enhancer on H19 promoter and result in increased gene expression.  
I, therefore, analyzed the methylation status of the CTCF binding sites within the H19 
imprinting domain in wild-type and Junb-deficient MEFs. For this propose, I isolated 
genomic DNA from wild-type and Junb-/- MEFs and subsequently treated the DNA with 
bisulfite. Treatment of DNA with bisulfite converts cytosine to uracil residues, but leaves 5-
methylcytosine residues unaffected, thus allowing us to discriminate between methylated and 
unmethylated cytosines. 
First, I analyzed the methylation status of the imprinted region encompassing the CTCF 
recognition sites by Combined Bisulfite Restriction Analysis (COBRA). During the course of 
this method, the regions of interest were amplified by PCR and the amplicons were digested 
with BstUI, a restriction enzyme containing the dinucleotide CG within its restriction site. By 
the bisulfite treatment, unmethylated cytosines were converted to uracil, leading to the loss of 
the BstUI restriction site. Thus, observation of an undigested PCR product is reminiscent of 
absence of DNA methylation and a digested PCR product is a sign for the presence of DNA 
methylation. Only the 1st, 3rd and 4th CTCF sites could be analyzed by COBRA since the 2nd 
CTCF site did not fulfill the necessary prerequisite of containing a BstUI restriction site (Fig. 
10A). While wild-type MEFs displayed approximately a 1:1 ratio of unmethylated and 
methylated CTCF sites (Fig. 10B), Junb -/- MEFs showed significantly elevated amounts of 
unmethylated amplicons for all three CTCF sites (Fig. 10B).  
Secondly, in order to analyze the methylation status of each individual cytosine located in the 
region of interest, bisulfite sequencing experiments were carried out for the 2nd and 4th CTCF 
site. The bisulfite sequencing revealed for the wild-type cells that 100% of the PCR 
amplicons covering both CTCF sites were methylated (Fig. 10C). By contrast, a significant 
increase of unmethylated cytosines (represented by empty circles) was observed in Junb-
deficient MEFs. Interestingly, the CTCF site number 2 displayed loss of methylation only in 
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the CTCF consensus sequence, while the 4th CTCF binding site displayed loss of methylation 
on a wide region encompassing the consensus sequence (Fig. 10C).  
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Taken together, these analyses revealed that methylation at the four CTCF binding sites is 
impaired or lost in Junb-deficient MEFs and that the molecular mechanisms regulating the 
methylation status of each CTCF site may be different. 
6.2 Junb is a novel decision maker for death or survival 
6.2.1 Junb is induced in response to ER stress  
To investigate whether Junb is causally implicated in the ER stress response, I analyzed the 
expression of Junb in wild-type and Junb-deficient MEFs following Tunicamycin application.  
Tunicamycin (Tm), a nucleoside antibiotic that inhibits the enzyme N-acetylglucosamine 
phosphotransferase blocks the synthesis of all N-linked glycoproteins and, thereby, causes 
ER stress. Tm treatment of wild-type cells resulted in a significant induction of Junb mRNA 
transcripts already 15, 30, and 45 minutes (data not shown) but with a maximum at 1 and 4 h 
post Tm application as measured by qRT-PCR (Fig. 11A). Analysis of Junb protein levels 
revealed a rapid upregulation of Junb starting 10 min post treatment, with a peak at 4 to 8 h 
and a decline to basal levels 24 h post treatment. No Junb protein was detectable in Junb-
deficient MEFs (Fig. 11B).  
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6.2.2 Loss of Junb results in increased expression of ER-located 
chaperones and to minor changes in UPR 
To investigate the role of Junb in ER stress, we monitored the expression of ER-located 
chaperones and UPR signaling molecules in Tm-treated wild-type and Junb-deficient MEFs. 
ER-located chaperones and enzymes, such as Grp78, Grp94 and Oxidoreductin-like 1, are 
essential for protein folding in the ER and are good markers of ER steady state and ER stress. 
Thus, I analyzed their mRNA expression in unchallenged as well as in Tm-treated MEFs 
(Fig. 12). qRT-PCR analyses revealed that untreated Junb-deficient MEFs harbored 
significantly increased endogenous levels of grp78, grp94 and oxidoreductin-like 1. 
Furthermore, treatment with Tm induced expression of all three chaperone mRNAs both in 
wild-type and Junb-/- MEFs. While mRNA transcripts levels were comparable between wild-
type and Junb-/- cells 4 and 8 h post Tm application, transcripts levels of all three chaperones 
were significantly increased in Junb-deficient MEFs 16 h post treatment (Fig. 12).  
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Furthermore, analysis of Grp78 protein revealed for Junb-deficient MEFs a delayed induction 
kinetics. While, in wild-type cells, Grp78 protein was already induced 4 h post treatment and 
reached its maximum levels at 8 h lasting until 24 h post induction, Grp78 protein in Junb-
deficient cells was only induced at 8 h with its maximum at 16 to 48 h post Tm application 
(Fig. 13A). A major event in the Grp78-triggered signaling of the UPR is the processing of 
Xbp1. In both wild-type and Junb-deficient MEFs, processed Xbp1 (Xbp1s) was detected 4 h 
post Tm treatment (Fig. 13B). Yet, kinetics and extent of Xbp1 processing appeared to be 
slightly different for Junb-/- MEFs with enhanced levels of spliced Xbp1s found 4 and 8 h 
post Tm treatment. To monitor PERK signaling, phosphorylation of eIF2α was determined. 
Phosphorylated eIF2α was already detected in unchallenged Junb-deficient MEFs (Fig. 13C). 
In response to Tm application, a further increase in phospho-eIF2α was found in Junb-
deficient MEFs, yet, the kinetics of induction was slightly delayed in comparison to wild-type 
cells. Finally, expression of the UPR-induced pro-apoptotic transcription factor CHOP was 
monitored. CHOP protein was induced in both wild-type and Junb-deficient MEFs with a 
maximal induction 16 h post Tm treatment (Fig. 13D). While the kinetics of CHOP induction 
was similar, total amount of CHOP protein was slightly diminished in Junb-/- cells.  
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In summary, unchallenged Junb-deficient cells show somewhat elevated chaperone 
expression being reminiscent of endogenous ER stress, however, Junb-/- cells are still able 
respond to the ER stress inducing agent Tm by initiating UPR signaling. 
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6.2.3 Junb deficiency renders cells resistant toward stress-induced 
apoptosis 
Sustained ER stress leads to the induction of cell death (Szegezdi et al., 2006). To determine 
the apoptosis rate in response to prolonged Tm treatment, wild-type and Junb-deficient MEFs 
were stained by AnnexinV and subsequently analyzed by flow cytometry (Fig. 14). No 
obvious differences in the rate of spontaneous apoptosis could be observed in cells left 
untreated. 40% of wild-type cells were AnnexinV-positive 24 h post treatment with Tm. By 
contrast, only 12% of Junb-deficient MEFs were positively stained for Annexin V. In order to 
determine whether MEFs were resistant towards ER stress-mediated apoptosis or whether 
they harbored a general apoptosis defect, MEFs were treated with stress stimuli such as 
proteasomal inhibitor (MG132) and UV. While MG132 and UV treatment induced 60% and 
40% AnnexinV positive cells, respectively, in wild-type MEFs, Junb knock-out cells were 
resistant towards both stresses displaying only 15% cells positively stained for AnnexinV. 
Importantly, treatment of both wild-type and Junb-/- with vehicle (DMSO) did not induce any 
significant cell death. Moreover, Junb-deficient MEFs were hypersensitive in response to a 
low dose of CD95L that efficiently induced apoptosis in these cells as evidenced by more 
than 40% AnnexinV positive cells, while wild-type cells were not responsive (10% positive 
cells).  
 
In conclusion, loss of Junb confers resistance toward stress stimuli-induced cell death, but 
Junb-deficient cells have the capacity of undergoing apoptosis upon death receptor activation. 
As the activation of caspases is a prerequisite for the induction of apoptosis, we assessed the 
processing of caspases upon Tm treatment by immunoblotting. In wild-type cells, the effector 
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caspase 3, and the initiator caspases 6 and 9 were activated 24 h post Tm treatment (Fig. 15), 
while in Junb-deficient MEFs, no (caspases 6 and 9) or only very marginal caspase 
processing (caspase 3) was detectable. To exclude a potential delay in caspase processing in 
Junb-/- cells, we also determined levels of cleaved caspases at later time points. Even at 32, 36 
and 48 h post Tm application no caspase processing was detected. As a read-out for caspase 
activity, the cleavage of the caspase-3 target PARP was determined. Whereas PARP was 
efficiently cleaved in wild-type MEFs, Junb-deficient MEFs exhibited no PARP cleavage 
(Fig. 15). Thus, Junb-deficient MEFs fail to undergo apoptosis in response to ER stress due to 
a failure of caspase activation. 
 
6.2.4 Junb-deficient MEFs exhibit a defective intrinsic apoptosis pathway  
Recently, Masud et al (Masud et al., 2007) have shown that ER stress induced apoptosis 
primarily depends on the mitochondrial intrinsic pathway. Activation of this intrinsic 
pathway results in cytochrome c release from the mitochondria. Cytochrome c subsequently 
triggers the formation of the apoptosome and eventually leads to the processing of caspase 9. 
As no caspase 9 processing was observed in Junb-deficient MEFs, I analyzed the release of 
cytochrome c from the mitochondria of wild-type and Junb-deficient MEFs in response to 
Tm treatment (Fig. 16). In wild-type MEFs, 18 h post Tm application, all cytochrome c had 
been released from the mitochondria as demonstrated by loss of co-staining with the 
mitochondrial marker Mito Tracker® by immunofluorescence analysis. By contrast, in Junb-
deficient cells, cytochrome c did not translocate to the cytoplasm at 18 h or even 48 h post 
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Tm treatment since cytochrome c staining was still overlapping with the mitochondrial 
marker at these time points (Fig.16, right panel).  
 
A prerequisite for cytochrome c release upon apoptosis induction is the oligomerization of 
Bax at the mitochondrial membrane that facilitates the formation of the MOMP 
(mitochondrial outer membrane pore). Bax oligomerization was measured by 
immunodetection of the crosslinked mitochondrial fraction. Oligomerization was detected 21 
h post Tm application in wild-type cells, while no Bax oligomerization was found in Junb-
deficient MEFs at this time point but could be detected 48 h post Tm treatment (Fig. 17A). 
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Thus, loss of Junb results in delayed Bax oligomerization upon prolonged ER stress which is 
causative of the absence of cytochrome c release from the mitochondria. 
6.2.5 Aberrant expression and post-translational modification of pro- and 
anti-apoptotic Bcl2 family members in Junb-/- MEFs 
Mitochondrial outer membrane pore formation is governed by the net balance of pro-
apoptotic Bcl-2 members such as Bax, Bad, Bak and Bim and anti-apoptotic Bcl-2 family 
members including Bcl-2, Bcl-xL. The net activity is determined via expression levels but 
also post-translational modification of Bcl-2 members.  
Thus, I investigated the expression and post-translational modification of key Bcl-2 members. 
Junb-deficient MEFs displays diminished protein levels of Bax both on whole cell extracts 
(Fig. 17B) and mitochondrial membranes (Fig. 17A). However, bax mRNA transcripts were 
not diminished in Junb-deficient MEFs (data not shown). Furthermore, levels of Bak, Bcl2, 
Bcl-xL were not affected in Junb-deficient MEFs (Fig. 17A).  
Recently, Zhang and colleagues revealed a crucial role of clusterin in the regulation of 
apoptosis by inhibiting Bax oligomerization (Zhang et al., 2005). Clusterin levels were 
elevated both on mRNA (Fig. 6) and protein levels (Fig. 17B) in Junb-deficient MEFs. In 
order to decipher the impact of increased clusterin expression on the cell death phenotype, 
clusterin mRNA levels were suppressed by siRNA technology in Junb-/- MEFs. Junb-null 
MEFs were infected with lentiviral particles encoding 4 different shRNAs against clusterin 
and one non-targeting shRNA. One week post infection and subsequent puromycin selection, 
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clusterin expression was measured by RT-PCR and immunoblot. Clusterin mRNA and 
protein levels could be efficiently suppressed upon infection with shRNAs number 1, 2 and 5 
(Fig. 18A and 18B), while cells infected with non-targeting control shRNA and shRNA 4 
showed clusterin levels similar to the ones measured in uninfected Junb-/- MEFs. To 
determine whether clusterin suppression may rescue the apoptosis failure, shRNA-infected 
Junb-deficient MEFs were treated with Tm and cell death was monitored morphologically. In 
contrast to wild-type cells, no cell death was observed in Junb-/- MEFs (Fig. 18C) in whose 
clusterin was efficiently knocked-down. Thus, increased clusterin levels are not responsible 
for the apoptosis resistance of Junb-deficient MEFs. 
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In order to decipher whether an imbalance of pro- and anti-apoptotic Bcl-2 members in favor 
for anti-apoptotic proteins may be causative for apoptosis resistance of Junb-deficient cells, I 
determined the post-translational modifications of the Bcl-2 family members Bim and Bad. 
Bim is phosphorylated on multiple serine and threonine residues by both pro-survival and 
pro-apoptotic kinases. While phosphorylation of Bim by the MAPK Extracellular signal 
Regulated Kinase (ERK) leads to its degradation by the proteasome (Hubner et al., 2008), 
pro-apoptotic Bim phosphorylation by JNK induces formation of the MOMP (Lei and Davis, 
2003), and subsequent cell death. Thus, I analyzed the Bim levels by immunoblot analysis. In 
wild-type cells, Bim protein levels were strongly induced between 1 and 4 h and again 24 h 
post Tm treatment. The Bim specific antibody detected a protein smear most likely due to a 
significant portion of slower migrating phosphorylated Bim. While no induction of Bim 
protein could be observed in Junb-deficient cells in response to Tm application, a slower 
migrating Bim, which is indicative for phosphorylated Bim, was very prominent in untreated 
Junb-deficient cells as well as in -/- cells harvested shortly post Tm treatment (Fig. 19, 0 up 
to 1 h post Tm treatment). At later time points Bim levels were induced with a maximum at 
24 h but in contrast to wild-type cells, no Bim phosphorylation even at late time points, 32 
and 48 h could be detected (Fig. 19).  
Bad is phosphorylated on the serine residues 112 by ERK and 136 by Akt, respectively, and 
subsequently sequestered in the cytoplasm by 14-3-3. Upon stress stimuli, Bad is 
dephosphorylated, translocates to the mitochondrial membrane and induces the formation of 
the MOMP, and subsequent cell death (Youle and Strasser, 2008). Thus, I analyzed the levels 
of Bad phosphorylation at S-112 and S-136 following Tm application in wild-type and Junb-
deficient MEFs. In wild-type cells, some Bad phosphorylation on both serine residues was 
detected from 30 min to 8 h post Tm treatment, whereas no Bad phosphorylation could be 
detected at 16 to 24 h post treatment when the cells undergo apoptosis (Fig. 19 compared to 
Fig. 14). By contrast, high levels of phosphorylated Bad were measured in unchallenged 
Junb-/- MEFs and phospho-Bad protein persisted up to  24 and 32 h post Tm treatment, the 
time point when wild-type cells undergo apoptosis.  
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Thus, Junb-deficient MEFs are different from wild-type cells by diminished protein levels of 
Bax and increased levels of clusterin. Yet, these alterations are not solely responsible for the 
cell death resistance of Junb-deficient MEFs. Most importantly, aberrant phosphorylation of 
Bcl-2 family members Bim and Bad observed in Junb-/- MEFs confers anti-apoptotic 
behavior. 
6.2.6 Imbalance in favor of anti-apoptotic Bcl2 family members is due to 
enhanced pro-survival signaling  
Bim and Bad are phosphorylated by the kinase Akt and the MAP kinases ERK and JNK. As 
altered and even more abundant p-Bim and p-Bad levels were observed in Junb-/- cells, I 
analyzed the activation of these upstream kinases in wild-type and Junb-deficient MEFs 
following Tm application. Strikingly, untreated Junb-deficient MEFs displayed elevated 
levels of phosphorylated Akt (Fig. 20A) and ERK (Fig. 20B). Although phosphorylation of 
Akt was further induced 1 h post Tm treatment in Junb-/- MEFs similarly to wild-type cells 
(Fig. 20A), levels of phosphorylated ERK only  marginally increased upon Tm treatment in 
wild-type and dramatically decreased upon Tm treatment in Junb-deficient MEFs (Fig. 20B). 
Tm-induced phosphorylation of JNK was identified as a major inducer of ER stress mediated 
apoptosis (Urano et al., 2000). In wild-type cells, JNK phosphorylation was only slightly 
induced at early time points following Tm application and prominent p-JNK levels were 
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detected  24 h post Tm treatment, at a time point when wild-type cells were apoptotic. By 
contrast, no p-JNK was found at any time point post Tm treatment in Junb-/- MEFs. Thus, 
Junb-deficiency results in an aberrant balance of pro-survival and pro-apoptotic signaling as 
apparent by major differences in p-Akt, p-ERK and p-JNK levels. 
 
The kinases Akt and ERK respond to activation of Phosphoinositide-3 Kinase (PI3K) and 
Ras elicited by extracellular stimuli. In order to decipher whether an increased PI3K activity 
in Junb-/- cells is causative for phosphorylated Akt and ERK signaling, wild-type and Junb-
deficient MEFs were treated with PI3K inhibitors. In order to ensure specific action of the 
inhibitors, two different PI3K inhibitors, Wortmannin and LY294002, were used. Treatment 
of wild-type and Junb-deficient MEFs with either inhibitor resulted in a decrease of p-Akt, p-
ERK and p-Bad on S136 (Fig. 21). Wortmannin, which has a very short half-life 
(Vanhaesebroeck and Waterfield, 1999), inhibited phosphorylation of Akt and ERK 1 h post 
application and lost its activity by 4 h (ERK) and 8 h (Akt) post treatment (Fig. 21A). By 
contrast, LY294002 required a minimum time span of 16 h in order to inhibit Akt and ERK 
phosphorylation (data not shown). 24 h post application, levels of phosphorylated Akt, ERK 
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and Bad on S136 were reduced to basal levels both in wild-type and Junb-deficient MEFs 
(Fig. 21B). 
 
Taken together, increased PI3K activity is causative of the enhanced pro-survival signaling 
and subsequent apoptosis resistance observed in Junb-deficient MEFs. 
6.2.7 Presence of (a) soluble factor(s) responsible for autocrine pro-
survival signaling in Junb-deficient MEFs. 
PI3K is activated downstream of numerous Receptor Tyrosine Kinases (RTKs) and G Protein 
Coupled Receptors (GPCRs) that directly or through adaptor proteins bind and activate PI3K. 
PI3K activity is, thus, carefully regulated by growth factor-receptor interactions (Stokoe, 
2005). In order to determine whether Junb-deficient MEFs express increased levels of soluble 
factors which would enhance PI3K activity, wild-type cells were cultured in presence of 
Junb-deficient MEFs in a transwell co-culture system as described in Figure 22A. Wild-type 
and Junb-/- MEFs were seeded at equal density in a porous insert positioned above a six-well 
and were allowed to grow for 48 h. Dishes were carefully shacked every 6 to10 h in order to 
avoid any growth factor deposition. Since the substrate on which cells grow can influence 
PI3K signaling, wild-type and Junb-deficient cells were co-cultured in both directions, 
meaning wild-type in the insert and Junb-null in the six-well as well as vice versa. After 48 h 
of incubation, whole cell extracts were prepared and analyzed by immunoblot. Levels of p-
Akt and p-ERK were independent of the substrate on which the cells were grown (Fig. 22B). 
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Importantly, co-culture of wild-type MEFs with Junb-/- resulted, in wild-type cells, in 
marginally increased levels of p-Akt, and prominent levels of p-ERK similar to those 
observed for unchallenged Junb-/- MEFs (Fig. 22B). In addition, co-culture did not reduce the 
levels of p-Akt and p-ERK in Junb-null MEFs, revealing that the soluble factor(s) is (are) 
present in excess and sufficient to sustain autocrine and paracrine signaling in both cell types 
at the same time. 
 
Previous experiments identified Junb as a repressor of many cytokines such as G-CSF and 
Csf2 (also called GM-CSF) in fibroblasts (Meixner et al., 2008; Saito et al., 2000; Szabowski 
et al., 2000). Since Csf2 has been described to induce phosphorylation of Akt and ERK in 
myeloid cells (Klein et al., 2000), I analyzed the impact of Csf2 overexpression in MEFs. As 
shown by RT-PCR in Figure 23A, Junb-deficient MEFs express large amount of Csf2 
mRNA. To decipher whether fibroblasts can respond to Csf2, we determined the levels of 
Csf2 receptor expressed in wild-type and Junb-/- MEFs. Csf2 receptor consists of 2 subunits: 
a cytokine specific alpha-chain (Csf2ra), which binds the ligand with low affinity, and a beta-
chain (Csf2rb), which forms only upon association with the alpha-chain a high affinity 
receptor. So far, two isoforms of the beta-chain have been described Csf2rb and Csf2rb2 
(Geijsen et al., 2001). RT-PCR analyses of two different pairs of wild-type and Junb-deficient 
clones revealed that Junb-/- MEFs expressed neither Csf2ra nor Csf2rb and only marginal 
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amounts of Csf2rb2 transcripts (Fig. 23B). By contrast, wild-type cells expressed the alpha 
chain Csf2ra but none of the Cs2rb isoforms.  
 
Moreover, RT-PCR performed on cDNA prepared from wild-type and Junb-null thymus as 
positive control for Csf2ra, Csf2rb and Csf2rb2 expression, revealed no difference of Csf2 
receptor expression between wild-type and Junb-null thymus. Thus, since MEFs do not 
express the functional Csf2 receptor, Csf2 can be excluded as the factor being responsible for 
increased p-Akt and p-ERK  
6.2.8 Pdgfb is a novel negatively regulated Junb target gene  
Platelet-derived Growth Factor (Pdgf) is a potent mitogenic growth factor acting on 
mesenchymal cells such as fibroblasts via Akt signaling (Heldin and Westermark, 1999). 
Pdgf family consists of Pdgf-a, -b, -c and -d which form either homo- or hetero-dimers. The 
Pdgfs bind to the protein kinase receptor Pdgfra and Pdgfrb, which also form dimers. 
Extensive studies have shown that, while Pdgf-aa homodimer binds only to Pdgfr-aa dimer, 
Pdgf-bb binds preferentially Pdgfr-bb dimer (Andrae et al., 2008). Thus, we measured mRNA 
transcript levels of Pdgfa, Pdgfb, Pdgfra and Pdgfrb by qRT-PCR. As described in Figure 
24A, levels of Pdgfa, Pdgfb, Pdgfra were significantly increased in Junb-deficient MEFs, 
while levels of Pdgfrb were slightly increased (1.8x, non significant). Although Junb null 
MEFs harbored increased levels of Pdgfa and Pdgfra mRNA and protein, no endogenous 
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phosphorylation of the Pdgfra could be detected by immunoblot (Fig. 24B). By contrast, 
elevated levels of Pdgfrb protein and endogenous phosphorylation of the Pdgfrb could be 
detected by immunoblot of Junb-deficient whole cell extracts (Fig. 24B). Thus, Pdgfb 
appears as a very good candidate being responsible for the enhanced endogenous levels of p-
Akt and p-ERK. 
 
Increased levels of Pdgfb mRNA in Junb-/- MEFs could be due to either increased 
transcription or enhanced mRNA stability. In order to discriminate between these two 
possibilities, wild-type and Junb-deficient MEFs were treated with the transcription inhibitor 
Actinomycin D (ActD) and levels of mRNA transcripts were quantified by qRT-PCR. 
Actinomycin D, a polypeptide antibiotic, binds to DNA at the transcription initiation complex 
                                                                                                                                       6. Results 
78 
 
and prevents elongation by RNA polymerase (Sobell, 1985). Treatment of MEFs with ActD 
for 4 h induced a 10-fold decrease in Pdgfb transcript levels in both wild-type and Junb-
deficient cells (Fig. 25).  Thus, mRNA stability is not affected in Junb-deficient MEFs and 
increased levels of Pdgfb mRNA in Junb-/- most likely results of increased transcription. 
 
In silico promoter analysis of Pdgfb highlighted the presence of two putative AP-1/TRE, one 
NF-κB, one Ets1 and one Sp1 transcription factor binding sites (Fig. 26A). In order to verify 
the ability of AP-1 and other transcription factors to bind to these putative sites in vitro, 
Electromobility Shift Assays (EMSA) were performed by incubation of biotin-labeled 
oligonucleotides with wild-type and Junb-deficient extracts and subsequent separation on a 
non-denaturing PAGE. The localization of transcription factor binding sites and 
oligonucleotides used for EMSA are given in figure legend 26A. EMSA analysis of the AP-
1/TRE binding site (-388) revealed the binding of a complex which was diminished in Junb-
deficient nuclear extracts (Fig. 26B left panel). Since the binding was competed by non-
biotinylated oligonucleotides encompassing the previously described consensus TRE of 
MMP13 promoter (Angel et al., 1987), this complex appears to contain AP-1. EMSA with the 
NF-κB site produced only a very weak complex and no difference in binding was observed 
between wild-type and Junb-deficient extracts (data not shown). When oligonucleotides 
encompassing the TRE and Ets1 binding sites (TRE/Ets1 -70/-87) were analyzed, the binding 
of a complex was observed with nuclear extracts of wild-type but not of Junb-deficient 
MEFs. Competition experiments using unlabelled oligonucleotides comprising the 
stromyelosin Ets1, and the consensus TRE sites were unsuccessful, suggesting that this 
complex was neither composed of AP-1 nor Ets1. Yet, this complex was competed with an 
oligonucleotide containing a mutated AP-1 site but the original Ets1 site plus flanking 
sequences, meaning that this unidentified factor binds to a sequence site located 3’ of the AP-
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1 recognition sequence within the oligonucleotide (Fig. 26B, middle panel). Sp1 interacted 
strongly with its binding site located at position -53 in wild-type MEFs, while its binding 
activity was reduced in nuclear extracts from Junb-/- MEFs (Fig. 26B, right panel).  
 
                                                                                                                                       6. Results 
80 
 
Taken together, the results identified in the Pdgfb promoter an AP-1/TRE binding site at 
position -388, an unidentified factor binding site at around -70 and a Sp1 binding site at -53, 
which were all less efficiently bound in absence of Junb.  
In order to study the impact of the identified factors on the promoter activity, luciferase 
reporter assays were performed. Therefore, three different Pdgfb promoter regions were 
cloned in front of the luciferase gene: one comprised the Sp1 site, the unidentified binding 
site and the NF-κB site (named short construct); the two other reporter constructs 
encompassed a wild-type or a mutated AP-1/TRE as well as the Sp1, the yet unidentified 
binding site and the NF-κB sites (wtTRE, mutTRE; Fig. 27A). Wild-type and Junb-deficient 
MEFs were transfected with these luciferase constructs and promoter activity was measured 
48 h post transfection. All three constructs displayed a 45-fold induction of luciferase activity 
compared to the empty vector in wild-type MEFs (Fig. 27B), indicating that the promoter 
activity was not affected by the mutation of the AP-1/TRE (-388) site. In Junb-deficient 
MEFs the luciferase reporter was only 15-fold induced when compared to empty vector and, 
in line with the findings received in wild-type cells, the promoter activity was not impaired  
upon mutation of the AP-1/TRE (-388) site (Fig. 27B). 
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Altogether, these results identified an AP-1/TRE binding site located at -388 of the Pdgfb 
promoter, but luciferase analyses showed that this binding site do not regulate the promoter 
activity. 
6.2.9 Re-expression of Junb rescues the apoptosis failure of Junb-deficient 
MEFs  
In order to ensure that solely the loss of Junb is responsible for the observed apoptosis 
resistance and to exclude that potential secondary mutations probably acquired during the 
immortalization process may account for the observed phenotype, Junb expression was 
restored in Junb-deficient MEFs. Therefore, wild-type and Junb-null MEFs were infected in 
parallel with retrovirus containing either an empty vector (+pMX) or a Junb expression 
vector (+pMX-Jb) both coexpressing GFP that facilitated the monitoring of transduction 
efficiency. Subsequently to retroviral infection, cells were selected with puromycin to obtain 
more than 95% cells transduced, as monitored by FACS analysis for GFP expression (data 
not shown). Re-expression of Junb in Junb-deficient MEFs resulted in a very high expression 
of Junb on protein level (Fig. 28A). Since the levels of Junb are very critical for the cells, 
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wild-type cells were as well infected with retrovirus containing Junb. Thus, wild-type MEFs 
could be obtained that express similar level of Junb as the Junb-transduced Junb-/- MEFs (Fig. 
28A). Pdgfb mRNA levels were measured by qRT-PCR. While retroviral infection resulted in 
a further mild non significant increase of Pdgfb transcripts in Junb-/- MEFs, Pdgfb mRNA 
transcripts were robustly suppressed in Junb-/- MEFs rescued with Junb (Fig. 28B). 
Furthermore, levels of p-Akt, p-ERK and p-Bad in Junb-rescued Junb-/- MEFs were 
normalized to wild-type levels (Fig. 28C). 
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Rescued cells were then treated with Tm and apoptosis was monitored by AnnexinV staining 
and subsequent FACS analysis (Fig. 29). No obvious differences in the rate of spontaneous 
apoptosis could be observed in cells left untreated (Fig. 29, left bars). While 45% wild-type 
cells were AnnexinV-positive upon 24 h treatment with Tm, only 35% of infected wild-type 
cells were stained with AnnexinV, meaning that infection of cells with retrovirus slightly 
impaired induction of cell death. Junb-rescued Junb-/- cells showed a minor increase in 
AnnexinV positive cell numbers 24h post Tm treatment while Junb-deficient cells did not 
undergo apoptosis (20% AnnexinV positive), Importantly, when the analysis was performed 
32h post Tm application, 35% of all Junb-rescued Junb-/-cells were AnnexinV positive. This 
number of apoptotic cells was similar to the one monitored for Junb over-expressing wild-
type MEFs (Fig. 29). At this time point, Junb-null MEFs infected with the empty retrovirus 
displayed only 22% AnnexinV positive cells and, thus, exhibited similar number as 
uninfected Junb-deficient cells. Importantly, treatment of all cell lines with vehicle (DMSO) 
did not induce any significant cell death (Fig. 29, right bars).  
 
Altogether, this experiment showed that re-expression of Junb in Junb-/- MEFs brings Pdgfb, 
p-Akt, p-ERK and p-Bad back to wild-type levels, and furthermore restores the ability of the 
MEFs to undergo apoptosis upon prolonged ER stress elicited by Tm treatment, meaning that 
solely the loss of Junb is responsible for the observed apoptosis resistance. 
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7 Discussion 
7.1 Junb as positive and negative transcription regulator 
Previous in vitro and in vivo experiments clearly defined Junb as both an activating and 
repressing transcription factor (Florin et al., 2004; Florin et al., 2006; Licht et al., 2006; 
Meixner et al., 2008; Schmidt et al., 2007; Szabowski et al., 2000). While the molecular 
mechanisms regulating AP-1 transcription activation were intensively studied, the 
mechanisms underlying transcription repression are so far poorly understood. In general, 
different mechanisms of gene repression have been proposed, involving inhibition of 
transcription initiation, inhibition or competition for activating factors as well as epigenetic 
mechanisms.  For Junb, it has been claimed that it acts as a repressor on its own by forming 
heterodimers with other AP-1 subunits that, as a result, exhibit a much weaker transactivation 
potential. It is still a mystery how Junb is able to discriminate among target gene to repress 
and to activate. The understanding of this selectivity process and the underlying molecular 
mechanism may help to design specific drugs that could interfere with Junb function and thus 
interfere with the evil features of Junb. Therefore, I investigated in the present work 
additional mechanisms by which Junb may represses genes, and I could identify Junb target 
genes which are epigenetically regulated through two different mechanisms: HDAC-
dependent deacetylation and DNA methylation.  
Although no apparent difference in acetylation of histones and expression of HDACs could 
be observed between wild-type and Junb-deficient MEFs, the analysis of gene expression 
following treatment by two independent HDAC inhibitors revealed a few genes that are 
regulated by HDAC-dependent mechanisms. Four different classes of genes were identified 
depending on their expression following HDAC inhibitor treatment.  
The first class of genes, which comprises lipoprotein lipase (lpl), clusterin (clu), mapk 
phosphatase 1 (mkp1) as well as others, had their expression induced by HDAC inhibitor 
both in wild-type and Junb-deficient MEFs. This suggests that these genes have the potential 
to be induced by HDAC inhibitors in a similar way in wild-type and Junb-deficient cells and 
excludes that the difference in basal expression may be due to increased acetylation levels of 
histones located on their promoter region in Junb-deficient cells. 
The second class of genes is of particular interest since expression of these genes is enhanced 
by HDAC inhibitors only in wild-type cells. It includes glutathione S-transferase alpha 4 
(gsta4), erythrocyte protein band 4.1 like 4b (epb4.1l4b) and inhibitor of DNA binding 1 
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(id1). The fact that the gene expression cannot be further induced upon HDAC inhibition in 
absence of Junb suggests that the repression mechanisms involve HDACs and that they are 
impaired in Junb-null MEFs. Possible mechanisms will be discussed in more details in a 
subsequent paragraph. 
The third identified class of genes shows no modification in their expression pattern upon 
treatment with HDAC inhibitors, suggesting that some other mechanisms may be involved. 
For instance, another transcription factor or co-activator may be super activated in Junb-
deficient cells and be responsible for the enhanced expression. Novel experimental 
approaches, such as reverse genetic screens by RNA interference on a genome-wide scale in 
Junb-deficient cells or a recently describes break-through technology that quantitatively 
evaluates within a cell activities of dozens of transcription factors simultaneously (Romanov 
et al., 2008) would be required to address this issue.  
The last and fourth class of genes finally comprises inhibitor of DNA binding 3(id3) and 
keratinocyte growth factor (kgf), that display decreased expression upon treatment with 
HDAC inhibitors. HDAC inhibitors are reported to affect cell cycle progression and induce 
cell death (Marks et al., 2001). Since the two identified genes are involved in cell growth, 
proliferation and differentiation (Benharroch and Birnbaum, 1990; Lasorella et al., 2001; 
Zebedee and Hara, 2001), it is highly probable that the toxicity of such compounds is the 
major cause of their down-regulation. 
Different mechanisms could be causative of the observed HDAC-dependent de-repression 
phenotype of the second class of genes. First, one could postulate that Junb may interact with 
a yet-to-be-identified HDAC and recruit it to the promoter of target genes. Indeed, several 
transcription factors recruit HDACs to promoters and thereby repress transcription in the 
absence of appropriate signals (Glass and Rosenfeld, 2000). For instance, HDAC3 binds to 
the N terminal region of unphosphorylated Jun and represses Jun activity. When Jun becomes 
phosphorylated by JNK in response to the activation of upstream signaling pathways, 
HDAC3 dissociates from Jun, thus, allowing Jun to transactivate genes (Weiss et al., 2003). It 
has been recently shown that such a de-repression mechanism occurs during inflammation for 
the very tightly controlled expression of the cytokine ccl2 following Interleukin-1 treatment 
(Wolter et al., 2008). If an HDAC-dependent mechanism is responsible for the de-repression 
of the described genes, one could expect endogenously increased levels of histone acetylation 
in the promoter region of derepressed target genes in Junb-deficient MEFs. Further 
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experiments, such as chromatin immunoprecipitation, are required to analyze acetylation 
levels of histones in the promoter region of those genes and to confirm the hypothesis. 
Secondly, lysine acetylation may be implicated in the repression mechanism. Lysine 
acetylation has been originally identified in histones, but occurs also in a significant number 
of non-histone proteins including transcription factors, nuclear regulators and various 
cytoplasmic proteins. Thus, lysine acetylation is not only crucial in nucleus and 
transcriptional regulation, but also appears to be essential for regulating the activity of 
proteins involved in different processes, such as cytoskeleton dynamics, energy metabolism, 
endocytosis, autophagy and even signaling from the plasma membrane (Yang and Seto, 
2008a). More than 80 transcription factors, including p53, Forkhead box transcription factors 
(FoxO) and STAT, are known to be modified by acetylation. Acetylation of p53 was 
intensively investigated and studies revealed that acetylation can enhance p53 DNA binding, 
binding to transcriptional co-activator such as CBP, as well as protein stability by precluding 
ubiquitination and subsequent degradation (Yang and Seto, 2008a). Further studies should 
show whether Junb is modified by acetylation and, if so, whether such post-translational 
modification might regulate Junb transactivation activity and transcription of gsta4, id1 and 
epb4.1l4b. Finally, for the case that no difference in the acetylation of the promoter of the 
previously described genes or no acetylation modification of Junb will be observed, a global 
comparative analysis of the acetylome may help to explain the differences in gene expression 
observed in Junb-deficient MEFs.  
Taken together, these data suggest that Junb regulates gene expression through a yet-to-be 
identified HDAC-triggered mechanism (Fig. 30B panel 1). Although Junb does neither 
regulate the histone H3 acetylation status nor the expression levels of HDACs, the data from 
the HDAC inhibitor experiment nevertheless state that some of the Junb target genes must be 
regulated by HDACs. Further studies will be required to underline the molecular mechanisms 
responsible and to decipher whether Junb represses the identified genes by recruiting an 
HDAC to their promoter, or whether Junb activity by itself is regulated via acetylation or 
whether absence of Junb results in abnormal post-translational modifications of another 
regulator or transcription factor. 
 
With regard to gene repression by DNA methylation, my work revealed an essential role for 
Junb in the setting and/or maintenance of the imprinting of the non-coding RNA H19. H19 
was identified as the most deregulated transcript in Junb-deficient MEFs by previous global 
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gene expression analysis (Florin et al., 2004). Most importantly, I could confirm that solely 
the loss of Junb is responsible for the impaired expression of H19 since re-expression of Junb 
in Junb-deficient MEFs suppressed H19 expression. Although H19 is one of the first 
imprinted genes discovered, its function has not yet been fully unraveled but much effort has 
been invested to understand its transcription regulation. While the expression of key 
regulators of H19 transcription, such as CTCF, DNMT1 and DNMT3b, is unaffected in Junb-
deficient MEFs, analyses of methylation by using two different techniques revealed a loss of 
methylation of the imprinting control region in absence of Junb. Surprisingly, the results 
obtained for wild-type cells by the two techniques used were not consistent. While the 
COBRA assay revealed an expected 50:50 ratio for unmethylated and methylated DNA, 
being consistent with one maternally imprinted allele, bisulfite sequencing analyses revealed 
almost 100% of methylation of all sites analyzed. Different reasons, which have been 
previously described, could be responsible for this difference. It has been reported that a bias 
could emerge in bisulfite sequencing from PCR amplification, sub-cloning into sequencing 
vector and transformation into bacteria due to a higher affinity of primers or ligase for DNA 
comprising cytosine residues (reminiscent of DNA methylation before the bisulfite 
conversion) versus DNA with uracil/thymidine residues (reminiscent of absence of DNA 
methylation before the bisulfite conversion) (Grunau et al., 2001; Warnecke et al., 1997). In 
the present work, both approaches have been carried out from the same PCR amplification 
products, therefore, I conclude that the bias, most likely, arose from a preferential sub-
cloning or transformation of the PCR amplicons derived from previously methylated DNA 
rather than from a differential PCR amplification per se. Despite the presence of this bias, 
both methods revealed a loss of methylation of all four CTCF binding sites in Junb-deficient 
MEFs. In addition, bisulfite sequencing allows the determination of the methylation status of 
each cytosine residue in the region of interest. Interestingly, while the region encompassing 
the second CTCF binding site showed a loss of methylation of only the residues 
encompassing the consensus sequence, the fourth CTCF site displayed a loss of methylation 
for the whole region surrounding this binding site. This suggests that the molecular 
mechanisms responsible for the methylation regulation of both sites may be different.  
Although Junb does regulate neither the expression of CTCF nor of DNA methyltransferases, 
it may regulate the targeting of these enzymes to the DNA and/or their activity. In silico 
analysis of the insulator revealed the presence of a TRE site (5’-TGA C TCA-3’) located 
between the third and fourth CTCF consensus binding site. It will be crucial to determine 
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whether this site is required and essential for the regulation of imprinting by Junb. For this 
purpose, it will be important to confirm in future experiments in vitro and in vivo binding of 
Junb and, if a binding is confirmed, to test its impact by reporter assay and mutagenesis.  
It is feasible to postulate that Junb may interact with a DNA methyltransferase and may even 
recruit DNA methylation activity to the insulator via the identified AP-1 binding site. Indeed, 
there is increasing evidence that transcription factors can directly bind to DNA 
methyltransferases and recruit the enzyme specifically to some promoters, in a similar way as 
described above for HDACs. For instance, the transcription factor Myc associates with 
DNMT3a and, through the DNA-binding protein Miz-1, targets DNA methylation and 
silencing of p21Cip1 gene (Brenner et al., 2005). 
Moreover, H19 is located in an imprinted cluster with Igf2 and the expression of the two 
genes is differentially regulated by the same molecular determinant, namely the insulator. If 
the insulator is unmethylated, CTCF binds to its DNA sequence and creates a boundary 
which restricts the activity of the common downstream enhancer on H19 gene. Due to the 
fact that, in absence of Junb, the insulator undergoes demethylation, the expression of Igf2 
should be reduced. However, preliminary analyses revealed that Igf2 expression is rather 
enhanced in Junb-deficient MEFs. This suggests that, in addition to its impact on imprinting, 
Junb may regulate Igf2 and/or H19 expression directly through their promoters and further 
experiments shall address those questions. 
The data obtained in the present work revealed for the first time an implication of Junb and 
AP-1 in imprinting and DNA methylation (Fig. 30B panel 2). Thus, it will be challenging to 
determine whether Junb and AP-1 regulate the DNA methylation of other imprinting clusters 
or promoters. For this purpose, further experiments such as analyses of DNA methylation 
pattern on a genome-wide level by methyl-DNA immunoprecipitation or genome-wide 
bisulfite sequencing are required.  
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Altogether, this work confirms that Junb can repress genes by other mechanisms than 
absorbing the transcriptional activity of Jun and other AP-1 members (Fig. 30). Apparently, 
the molecular mechanisms involved in such a regulation are novel and very unusual for an 
AP-1 member, thus, they could not be fully deciphered during the course of this work. Many 
different possible mechanisms have been proposed and further experiments are required to 
confirm or exclude the hypotheses described above. Since impaired epigenetic modifications 
of the genome, including aberrant DNA methylation pattern and loss of imprinting, are 
observed in many tumors, the understanding of how Junb and AP-1 influence such processes 
will be of great importance in order to develop new possible therapies against cancer. 
7.2 Junb is a novel decision maker for death or survival  
The implication of AP-1 in stress response is very complex since it can have opposite 
function, being either pro-apoptotic or anti-apoptotic. Indeed, the net function depends on the 
relative abundance of AP-1 subunits, the composition of AP-1 dimers, the cell type, the 
cellular environment and the stimulus. Previous work based on in vivo mouse models and in 
vitro cell culture models defined a crucial role for one AP-1 member, Junb, in cellular 
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hypoxia and hypoglycemia responses. In the present work, I investigated the role of Junb in 
ER stress, a condition that has been described to contribute to hypoxia tolerance and tumor 
progression. Loss of Junb resulted in minor change in UPR, but most intriguingly Junb-
ablated MEFs were unable to undergo apoptosis upon prolonged ER stress albeit they were 
able to sense ER stress. Remarkably, Junb-deficient MEFs were also resistant towards 
apoptosis in response to DNA damaging agents or proteasome inhibitors suggesting a general 
defect in stress-induced apoptosis due to very high levels of activated pro-survival kinases 
elicited by an autocrine loop and resulting in failure in mitochondria permeabilization and 
subsequent caspases activation. Very importantly, apoptosis resistance could be solely 
attributed to the absence of Junb and not to additional mutations acquired during spontaneous 
immortalization of the MEFs. 
First, I found that Junb participates in the ER stress response as it is strongly induced on both 
mRNA and protein levels in response to Tunicamycin, which promotes ER stress by blocking 
protein glycosylation. Surprisingly, although Junb is described as an immediate early gene, 
whose expression is induced very fast after stress and rapidly returns to basal levels, Junb 
protein levels stayed high until 8 to 12 h post Tm application. Interestingly, such prolonged 
Junb induction was never observed so far for any kind of stress stimulus. At least two 
different causes could account for this observation: the specific requirement of Junb for the 
ER stress response or as a consequence of a cell cycle arrest. In an attempt to re-establish 
cellular homeostasis, the UPR will eventually results in cell cycle arrest. eIF2α, 
phosphorylated by PERK, has been proposed to block cyclin D1 protein translation, thus, 
causing cyclin D1 degradation and G1 phase arrest (Brewer and Cadman, 2000; Brewer and 
Diehl, 2000). In the past, it has been reported that the Junb is regulated during cell cycle 
progression with a peak at S/early G2 phase and a breakdown at M phase (Bakiri et al., 
2000). Besides, Junb regulates cell cycle via its target genes p16/Ink4a, cyclin A, cyclin A2 
and cyclin D1 (Andrecht et al., 2002; Bakiri et al., 2000; Farras et al., 2008; Passegue and 
Wagner, 2000). Moreover, the degradation of Junb at the M phase by the proteasome is 
absolutely required for proper cell cycle progression, since constitutive Junb expression 
results in cell cycle arrest at late G2/early M phase (Farras et al., 2008). Thus, it is feasible 
that the prolonged Junb induction is a consequence of cell cycle arrest. However, Junb could 
equally well be required for a proper late ER stress response. For instance, Junb-activated 
target genes may be involved in late UPR or may contribute to UPR induced cell cycle arrest. 
It will be a challenge to dissect cause and consequence as well as Junb direct and indirect 
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functions in this respect. Future experiments, incorporating cell cycle analysis along with 
UPR studies with synchronized wild-type and Junb-deficient MEFs, may be helpful in 
addressing these questions. 
Since Junb was induced upon ER stress, I investigated whether it is involved in UPR by 
monitoring key UPR factors in wild-type and Junb-deficient MEFs. Only minor differences 
were observed in ER stress sensing and induction. Untreated as well as Tm-treated Junb-
deficient MEFs harbored increased mRNA levels of the ER-located chaperones grp78 and 
grp94 and of the oxidoreductase and protein disulfide isomerase cofactor oxidoreductin-like 
1. It appears unlikely that Junb, on its own, transcriptionally regulates all these three 
chaperones, moreover because differences in expression were only minor although 
significant, between 1.5 and 2.5 fold. Thus, increased levels of these factors may rather be a 
consequence of an increased requirement for ER folding capacity in absence of Junb. Indeed, 
while Junb-deficient MEFs produce about 50% less protein (Textor B and Schorpp-Kistner 
M, unpublished data), they express much more mRNA coding for cytokines and growth 
factors. Assuming that these factors once being translated have to transit through the ER, 
then, Junb-/- MEFs would require a much higher capacity of the ER chaperone machinery 
than wild-type cells. This could be reflected by the enhanced chaperone expression levels but 
also by different kinetics in the UPR. Indeed, minor differences were observed in the kinetics 
of Grp78 and CHOP protein induction and of XBP1 splicing, while eIF2α was already 
endogenously phosphorylated in Junb-deficient MEFs. Furthermore, increased Grp78 and 
Grp94 protein expression has been extensively correlated to resistance towards apoptosis and 
tumorigenesis (Moenner et al., 2007). eIF2α phosphorylation by PERK prevents as well ER 
stress-induced cell death as it was shown that PERK-deficient cells are more susceptible to 
apoptosis in response to ER stress (Harding et al., 2000b). However, due to the fact that 
apoptosis induction was as well impaired upon proteasomal inhibition and DNA damage, 
both endogenous increased Grp78 expression and phosphorylation of eIF2α are presumably 
not responsible for the apoptosis phenotype observed in absence of Junb.  
Interestingly, Junb-deficient MEFs had the capacity to undergo apoptosis upon death receptor 
activation elicited by low concentrations of ectopically applied CD95L/FasL and were even 
more sensitive than wild-type cells. This is presumably due to increased levels of the receptor 
CD95/Fas on the surface of Junb-deficient MEFs (Bierbaum H, 2002). Thus, these data 
corroborate previous observations that AP-1 plays a dual role in cell survival and apoptosis 
depending on the type of stress stimulus. 
                                                                                                                                 7. Discussion 
92 
 
Resistance towards apoptosis and absence of caspase activation in cells lacking Junb could be 
ascribed to an in impairment in Bax expression and oligomerization, in mitochondria 
membrane permeabilization and in cytochrome c release into the cytosol. Bax protein but not 
mRNA levels were diminished in Junb-deficient MEFs, suggesting that Bax is not a 
transcriptional Junb target. However, Junb loss may influence Bax translation or protein 
stability. Indeed, various reports highlighted the fact that some factors may regulate apoptosis 
through modulation of Bax stability. For instance, the E6 protein from human papillomavirus 
16 and the glucosidase inhibitor pentagalloylglucose regulate the proteasomal degradation 
and protein stability of Bax (Chen and Lin, 2004; Magal et al., 2005).  
Both, Bax oligomerization and mitochondria pore formation is tightly orchestrated by Bcl-2 
protein family members and other proteins such as clusterin. Intracellular clusterin has been 
reported to interact with activated Bax, thus impeding Bax oligomerization and subsequent 
cytochrome c release (Zhang et al., 2005). Clusterin, first identified as Junb target gene upon 
global gene expression profiling (Florin et al., 2004), was indeed highly expressed in Junb-
deficient MEFs both on protein and mRNA level. However, increased levels of clusterin were 
not responsible for the block of apoptosis since knock-down of clusterin in Junb-deficient 
MEFs by siRNA technology did not rescue the apoptosis phenotype. 
Further analyses revealed aberrant post-translational modifications of the Bcl-2 family 
members Bim and Bad and enhanced upstream pro-survival signaling in absence of Junb. 
Functional regulation of Bim-dependent apoptosis is achieved via the regulation of its 
expression and via post-translational modification of the Bim protein by phosphorylation. 
Bim is phosphorylated on multiple residues by members of the MAPK family, including 
ERK, JNK and p38. While many studies have shown that ERK-dependent phosphorylation of 
Bim on the serine residues S-55,-65 and -73 targets Bim for proteasomal degradation, two 
reports provided evidence that ERK-dependent phosphorylation of BimEL attenuated its 
apoptotic activity independently of effects on protein stability (Collins et al., 2005; Wang et 
al., 2004). Bim is also phosphorylated on threonine 112 that is a target of both ERK and JNK 
signaling pathways. While JNK phosphorylates T-112 in response to UV radiation, ERK 
mediates phosphorylation at this site upon serum stimulation. Analysis of mice with germline 
mutations for the major Bim phosphorylation sites revealed furthermore that phosphorylation 
on S-55/65/73 negatively regulates BimEL expression and function, while JNK-triggered 
phosphorylation of Thr-112 increases the apoptotic activity of Bim (Hubner et al., 2008).  
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Due to the lack of antibodies recognizing specifically the phosphorylated residues, I 
investigated phosphorylation of Bim by the appearance of a slower migrating band on a 
denaturing polyacrylamide gel. In contrast to wild-type MEFs, unchallenged Junb-deficient 
MEFs harbored already increased levels of phosphorylated Bim while the late Tm-induced 
Bim phosphorylation that in wild-type cells coincides with JNK activation, was missing. One 
can speculate that the basal Bim phosphorylation is mediated by abundant p-ERK observed in 
Junb-/- cells. Intriguingly, this pro-survival signaling results at least in our cell culture model 
not in a phosphorylation-triggered proteasomal degradation of Bim but at least in an 
attenuation of its pro-apoptotic activity. Most importantly, Junb-deficiency leads to increased 
phosphorylation of a second pro-apoptotic BH3-only protein Bad. Both, ERK-mediated 
phosphorylation of Bad on serine residue S-112 as well as Akt-triggered phosphorylation on 
serine residue S-136 were robustly increased in logarithmically growing Junb-deficient 
MEFs. Bad has been shown to link survival signals to the mitochondrial cell death 
machinery. Growth factor-triggered Bad phosphorylation by Akt and its subsequent 
sequestration into the cytoplasm by 14-3-3zeta is considered as a major mechanism for 
survival factor-mediated block of apoptosis (Youle and Strasser, 2008). Concordantly, 
analyses of the upstream signaling pathways revealed enhanced PI3K activity and abundant 
p-ERK and p-Akt levels in unchallenged MEFs lacking Junb. Interestingly, JNK activation 
was completely abolished in Junb-deficient MEFs and most likely due to the imbalance 
between life and death cues in favor for pro-survival signaling. Indeed, there is evidence that 
Akt phosphorylates the JNK kinase ASK1 on S-83 and, thereby, inhibits JNK activation 
(Aikin et al., 2004).  
With regard to the present knowledge on the BH3-only proteins Bad and Bim as upstream 
initiators of the intrinsic apoptotic pathway, it is obvious that survival factor-induced ERK 
and Akt-mediated phosphorylation of Bim and Bad, respectively, and the subsequent 
inhibition of their pro-apoptotic activity is finally causative of the apoptosis resistance of 
Junb-deficient cells. 
Co-culture experiments clearly pointed out that one or multiple soluble factor(s) must be 
highly expressed in the absence of Junb and be responsible for autocrine pro-survival feed-
forward loop (Fig. 31). Previous studies showed that Junb negatively regulates the 
transcription of multiple growth factors and cytokines, including Kgf, Lipocalin-2, Csf2 
(Florin et al., 2006; Szabowski et al., 2000), and G-CSF (Meixner et al., 2008). In line with 
that, in vivo and in vitro phenotypes observed in absence of Junb have been associated to 
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alterations in expression levels and kinetics of cytokines. For instance, while impaired 
expression of Csf2 and Kgf are causative of skin abnormalities (Florin et al., 2006), increased 
levels of G-CSF obtained upon epidermal Junb-deficiency causes skin ulcerations, 
myeloproliferative disease and low bone mass (Meixner et al., 2008).  
Among the factors described here above, Csf2 appeared as potential candidate since it has 
been reported to induce phosphorylation of Akt and ERK in myeloid cells (Klein et al., 
2000). However, Csf2 could be excluded as the factor being responsible for increased 
phosphorylated Akt and ERK since Junb-deficient MEFs did not express the two subunits 
composing the Csf2 receptor. 
Further candidate factors included Pdgf, which is very potent mitogenic growth factor acting 
on mesenchymal cells such as fibroblasts and induces Akt and ERK activation (Heldin and 
Westermark, 1999). The expression of the ligands Pdgfa and Pdgfb as well as their respective 
receptors Pdgfra and Pdgfrb were elevated in absence of Junb; in particular, mRNA levels of 
Pdgfb and protein levels of Pdgfrb were highly up-regulated (Fig. 31).  
 
 
 
Pdgfb, discovered more than 30 years ago, is the cellular homologue of the product of the 
retroviral oncogene v-sis of simian sarcoma virus (SSV). v-sis is sufficient to confer the 
transforming activity of SSV and SSV transformation involves autocrine growth stimulation 
by the PDGF-like molecule v-sis, thus, demonstrating for the first time the importance of 
autocrine growth stimulation in neoplastic transformation and cancer (Doolittle et al., 1983). 
Since then, three additional Pdgf genes have been characterized: Pdgfa, Pdgfc and Pdgfd. All 
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Pdgfs form dimers of disulfide-linked polypeptide chains and act via the receptor tyrosine 
kinase Pdgfra and Pdgfrb. The possible Pdgf-Pdgfr interactions are multiple and complex and 
include the formation of receptor heterodimers (Andrae et al., 2008; Heldin and Westermark, 
1999). However, in vivo there is functional evidence only for a few interactions. For instance, 
Pdgf-aa interacts with Pdgfr-aa and Pdgf-bb with Pdgfr-bb (Andrae et al., 2008). Pdgfs have 
crucial roles during development and increased Pdgf activity has been linked with several 
diseases and pathological conditions, such as cancer. Numerous studies demonstrated that 
autocrine Pdgfb signaling confers self-sufficiency in growth signals but per se does not cause 
malignant cell behavior. Thus, Pdgfb signaling contributes to tumorigenesis by driving the 
proliferative expansion of pre-neoplastic and/or genetically unstable cell clones, which will 
eventually become fully malignant through further genetic alteration (Andrae et al., 2008). 
Moreover, a multifaceted role of Pdgf in cancer biology is now emerging as Pdgf signaling 
plays, in addition to providing a cell-autonomous proliferative stimulus, a role in invasion 
and in metastasis.  
Among all Pdgf members, Pdgfb appeared as the best candidate responsible for the enhanced 
pro-survival signaling observed in Junb-deficient cells due to its strong overexpression and 
due to the observed enhanced phosphorylation of Pdgfrb in Junb-deficient MEFs. However, 
further experiments, including siRNA-mediated knock-down of Pdgfb in Junb-ablated MEFs, 
are needed to corroborate the impact of Pdgfb on the pro-survival phenotype and concomitant 
apoptosis resistance. 
In this work, I identified Pdgfb as novel negatively regulated Junb-target gene. A promising 
TRE/AP-1 binding site was identified in the proximal promoter of Pdgfb. Although, I could 
confirm in vitro binding of AP-1 to this consensus site, reporter gene assay and mutagenesis 
analyses revealed that this TRE element was not the site through which repression of Pdgfb 
was achieved. Besides, other transcription factor binding sites, including a Sp1 and a yet-to-
be identified site, have been characterized, but none of these sites was responsible for the 
repression of Pdgfb by Junb. Further analyses revealed three distal TRE-related CRE 
elements located at around -4000 relative to transcription initiation site. Preliminary results 
suggest that two of these sites are bound by AP-1 in vitro and further experiments will 
address the impact of these two distal CRE sites on Pdgfb transcription regulation by reporter 
gene assays and mutagenesis. One could hypothesize that an intrachromosomal loop 
involving the CRE and/or TRE binding sites could bring multiple transcription factors 
together and, thus, tightly regulate Pdgfb transcription. Such regulatory loop has been 
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reported for the transcriptional regulation of the Jun promoter, where phosphorylated Jun 
interacts with TCF4 and beta-catenin and form a ternary complex on the promoter, thus, 
regulating intestinal tumorigenesis (Nateri et al., 2005). 
In addition to its impact on tumorigenesis, Pdgfb has important tasks in embryonic 
development. Endothelial expressed Pdgfb plays a crucial role in the recruitment of vascular 
smooth muscle cells (vSMC) and pericytes during embryogenesis (Hellstrom et al., 1999). 
Indeed, Pdgfb and Pdgfrb null embryos display pericyte and vSMC deficiency already at the 
onset of angiogenic sprouting. In spite of mural cell hypoplasia, the embryos continue to 
develop until embryonic day E16-E19 when finally widespread hemorrhage and edema cause 
embryonic lethality (Leveen et al., 1994). In addition, paracrine Pdgfb signaling plays a role 
in tumorigenesis by recruiting stromal cells, thereby inducing tumor angiogenesis and 
facilitating metastasis and drug resistance (see for review Andrae et al., 2008). Other studies 
reported that overexpression of Pdgfb even decreased colorectal and pancreatic cancer 
growth by increasing tumor pericyte content (McCarty et al., 2007). With regard to the 
numerous roles of Pdgfb signaling in fibrotic diseases, cancer and vascular disorders, it will 
be very important to prove that the negative regulation of this growth factor by Junb is also of 
relevance in vivo. It will be of high interest to investigate whether mice with conditionally 
ablated Junb display striking differences in Pdgfb signaling and whether some of the 
observed phenotypes can be attributed to aberrant Pdgfb signaling. 
 
Altogether, our results identified Junb as tumor suppressor since its absence in mouse 
embryonic fibroblasts results in resistance towards apoptosis due to an enhanced autocrine 
loop (Fig. 32). However, many studies, including the present one, which addressed the impact 
of Junb on apoptosis and cancer, suggest diverse even contradictory functions of Junb. For 
instance, previous work has suggested a tumor suppressor role of Junb in myeloid cells. 
Absence of Junb in myeloid cells in mice results in CML due to an uncontrolled expansion of 
LT-HSC and GMP. Increased Csf2 expression in Junb-deficient myeloid precursor cells 
initiates an autocrine loop favoring increased proliferation and decreased apoptosis (Passegue 
and Wagner, 2000). Additionally, high systemic levels of G-CSF resulting from the absence 
of Junb in epidermis cause as well myeloproliferative disease by favoring myeloid cell 
proliferation (Meixner et al., 2008). By contrast, Junb acts as tumor promoter in beta cells. 
Knock-down of Junb by siRNA in pancreas beta cells results in higher sensitivity towards the 
chemical ER stress inducer cyclopiazonic acid, while overexpression of Junb protects beta 
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cells from cytokine-induced cell death due to diminished iNOS levels (Gurzov et al., 2008b). 
Moreover, partial reduction of Junb levels by siRNA in wild-type murine fibroblasts causes 
increased proliferation and tumorigenicity, whereas in Jun-deficient cells it induces p53-
independent cell cycle arrest and apoptosis. Finally, Junb knock-down combined with JNK 
inhibition in melanoma B16 cancer cells results in cell cycle arrest and apoptosis-inducing 
factor-dependant apoptosis (Gurzov et al., 2008a). Altogether, these findings suggest that the 
role of Junb in apoptosis regulation is very complex and may depend on many parameters 
such as the cell type, transformation of the cells, the amount of Junb, as well as the balance 
between all AP-1 members.  
 
 
 
In conclusion, negative regulation of cytokines by Junb is of unequivocal importance to 
suppress pro-inflammatory and pro-tumorigenic phenotypes. Due to the fact that Junb has 
double-faced functions, it cannot be a rational therapeutical target. However, understanding 
how Junb represses gene and, most importantly, specific targeting this mechanism would 
represent a promising therapeutic approach in the future in order to treat inflammatory 
disease and cancer.  
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